Teleflex (TFX) 10-Q 31 Oct 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 29, 2019	Oct. 29, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 29, 2019
Document Transition Report	false
Entity File Number	1-5353
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-1147939
Entity Address, Address Line One	550 E. Swedesford Rd., Suite 400
Entity Address, City or Town	Wayne,
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	610
Local Phone Number	225-6800
Title of 12(b) Security	Common Stock, par value $1.00 per share
Trading Symbol	TFX
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,295,915
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000096943
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Income Statement [Abstract]
Net revenues	$ 648,319	$ 609,672	$ 1,914,410	$ 1,806,768
Cost of goods sold	272,639	267,099	821,064	788,147
Gross profit	375,680	342,573	1,093,346	1,018,621
Selling, general and administrative expenses	229,896	214,894	693,775	660,148
Research and development expenses	27,984	26,365	82,729	78,410
Restructuring and impairment charges	1,268	19,209	20,348	77,625
Gain on sale of assets	(1,089)	0	(3,828)	0
Income from continuing operations before interest and taxes	117,621	82,105	300,322	202,438
Interest expense	19,545	27,171	62,995	79,763
Interest income	(470)	(320)	(1,281)	(776)
Income from continuing operations before taxes	98,546	55,254	238,608	123,451
(Benefit) taxes on income from continuing operations	(130,383)	(1,286)	(115,567)	14,532
Income from continuing operations	228,929	56,540	354,175	108,919
Operating (loss) income from discontinued operations	(9)	(83)	(1,291)	1,246
Tax benefit on operating income (loss) from discontinued operations	(9)	(67)	(317)	(47)
Loss from discontinued operations	0	(16)	(974)	1,293
Net income	$ 228,929	$ 56,524	$ 353,201	$ 110,212
Basic:
Income from continuing operations (in dollars per share)	$ 4.95	$ 1.23	$ 7.67	$ 2.39
Income (loss) from discontinued operations (in dollars per share)	0	0	(0.02)	0.03
Net income (in dollars per share)	4.95	1.23	7.65	2.42
Diluted:
Income from continuing operations (in dollars per share)	4.85	1.21	7.53	2.33
Loss from discontinued operations (in dollars per share)	0	0	(0.02)	0.03
Net income (in dollars per share)	$ 4.85	$ 1.21	$ 7.51	$ 2.36
Weighted average common shares outstanding
Basic (in shares)	46,248	45,851	46,156	45,587
Diluted (in shares)	47,176	46,815	47,051	46,785

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 228,929	$ 56,524	$ 353,201	$ 110,212
Other comprehensive income (loss), net of tax:
Foreign currency translation, net of tax of $0, $(3,505), $0, and $0, for the three and nine months periods, respectively	(39,894)	14,387	(27,562)	(30,130)
Pension and other postretirement benefit plans adjustment, net of tax of $(494), $(363), $(1,330), and $(1,253) for the three and nine months periods, respectively	1,560	1,215	4,248	4,111
Derivatives qualifying as hedges, net of tax of $64, $(308), $146, and $(419) for the three and nine months periods, respectively	(260)	1,651	(102)	1,943
Other comprehensive (loss) income, net of tax:	(38,594)	17,253	(23,416)	(24,076)
Comprehensive income	$ 190,335	$ 73,777	$ 329,785	$ 86,136

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax	$ (7,045)	$ (3,505)	$ (8,804)	$ 0
Pension and other postretirement benefits plans adjustment, tax	(494)	(363)	(1,330)	(1,253)
Derivatives qualifying as hedges, tax	$ 64	$ (308)	$ 146	$ (419)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 257,544	$ 357,161
Accounts receivable, net	396,663	366,286
Inventories, net	472,594	427,778
Prepaid expenses and other current assets	81,531	72,481
Prepaid taxes	29,278	12,463
Total current assets	1,237,610	1,236,169
Property, plant and equipment, net	429,568	432,766
Operating lease assets	115,193
Goodwill	2,231,330	2,246,579
Intangible assets, net	2,175,673	2,325,052
Deferred tax assets	2,952	2,446
Other assets	64,856	34,979
Total assets	6,257,182	6,277,991
Current liabilities
Current borrowings	50,000	86,625
Accounts payable	100,630	106,709
Accrued expenses	91,569	97,551
Current portion of contingent consideration	135,168	136,877
Payroll and benefit-related liabilities	99,831	104,670
Accrued interest	19,686	6,031
Income taxes payable	3,299	5,943
Other current liabilities	30,180	38,050
Total current liabilities	530,363	582,456
Long-term borrowings	1,949,068	2,072,200
Deferred tax liabilities	468,945	608,221
Pension and postretirement benefit liabilities	72,016	92,914
Noncurrent liability for uncertain tax positions	11,084	10,718
Noncurrent contingent consideration	71,712	167,370
Noncurrent operating lease liabilities	104,136
Other liabilities	196,882	204,134
Total liabilities	3,404,206	3,738,013
Commitments and contingencies
Total shareholders' equity	2,852,976	2,539,978
Total liabilities and shareholders' equity	$ 6,257,182	$ 6,277,991

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018
Cash flows from operating activities of continuing operations:
Net income	$ 353,201	$ 110,212
Adjustments to reconcile net income to net cash provided by operating activities:
Loss (income) from discontinued operations	974	(1,293)
Depreciation expense	47,286	44,517
Amortization expense of intangible assets	112,661	111,974
Amortization expense of deferred financing costs and debt discount	3,313	3,548
Gain on sale of assets	(3,828)	0
Changes in contingent consideration	40,894	47,344
Impairment of long-lived assets	6,911	19,110
Stock-based compensation	20,037	16,469
Deferred income taxes, net	(140,963)	8,664
Payments for contingent consideration	(26,092)	(2,100)
Interest benefit on swaps designated as net investment hedges	(13,820)	0
Other	(7,142)	(10,928)
Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(41,221)	(29,830)
Inventories	(53,259)	(19,665)
Prepaid expenses and other assets	(13,184)	(6,468)
Accounts payable, accrued expenses and other liabilities	31,631	54,581
Income taxes receivable and payable, net	(28,232)	(43,191)
Net cash provided by operating activities from continuing operations	289,167	302,944
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(83,797)	(55,751)
Proceeds from sale of assets	3,135	0
Payments for businesses and intangibles acquired, net of cash acquired	(1,265)	(22,550)
Net interest proceeds on swaps designated as net investment hedges	8,330	0
Net cash used in investing activities from continuing operations	(73,597)	(78,301)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	25,000	0
Reduction in borrowings	(185,500)	(98,500)
Debt extinguishment, issuance and amendment fees	(4,964)	(188)
Net proceeds from share based compensation plans and the related tax impacts	14,014	18,666
Payments for contingent consideration	(112,006)	(73,152)
Dividends paid	(47,071)	(46,526)
Net cash used in financing activities from continuing operations	(310,527)	(199,700)
Cash flows from discontinued operations:
Net cash provided by (used in) operating activities	2,651	(701)
Net cash provided by (used in) discontinued operations	2,651	(701)
Effect of exchange rate changes on cash and cash equivalents	(7,311)	(1,524)
Net (decrease) increase in cash and cash equivalents	(99,617)	22,718
Cash and cash equivalents at the beginning of the period	357,161	333,558
Cash and cash equivalents at the end of the period	257,544	356,276
Non cash investing activities of continuing operations:
Property, plant and equipment additions due to build-to-suit lease transaction	0	28,147
Non cash financing activities of continuing operations:
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements	$ 0	$ 56,075

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Beginning Balance (in shares) at Dec. 31, 2017		46,871				1,704
Beginning Balance at Dec. 31, 2017	$ 2,430,531	$ 46,871	$ 591,721	$ 2,285,886	$ (265,091)	$ (228,856)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	56,184			56,184
Cash dividends	(15,447)			(15,447)
Other comprehensive income (loss)	82,690				82,690
Shares issued under compensation plans (in shares)		(97)				(43)
Shares issued under compensation plans	4,122	$ 97	992			$ 3,033
Deferred compensation (in shares)						(8)
Deferred compensation	322					$ 322
Settlements of warrants (in shares)						(132)
Settlements of warrants	(12)		(17,884)			$ 17,872
Ending Balance (in shares) at Apr. 01, 2018		46,968				1,521
Ending Balance at Apr. 01, 2018	2,561,466	$ 46,968	574,829	2,329,699	(182,401)	$ (207,629)
Beginning Balance (in shares) at Dec. 31, 2017		46,871				1,704
Beginning Balance at Dec. 31, 2017	2,430,531	$ 46,871	591,721	2,285,886	(265,091)	$ (228,856)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	110,212
Other comprehensive income (loss)	(24,076)
Ending Balance (in shares) at Sep. 30, 2018		47,192				1,235
Ending Balance at Sep. 30, 2018	2,507,065	$ 47,192	565,319	2,352,648	(289,167)	$ (168,927)
Beginning Balance (in shares) at Apr. 01, 2018		46,968				1,521
Beginning Balance at Apr. 01, 2018	2,561,466	$ 46,968	574,829	2,329,699	(182,401)	$ (207,629)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	(2,496)			(2,496)
Cash dividends	(15,491)			(15,491)
Other comprehensive income (loss)	(124,019)				(124,019)
Shares issued under compensation plans (in shares)		(114)				(2)
Shares issued under compensation plans	14,300	$ 114	13,992			$ 194
Deferred compensation	235		235
Settlements of warrants (in shares)						(140)
Settlements of warrants	(14)		(19,019)			$ 19,005
Ending Balance (in shares) at Jul. 01, 2018		47,082				1,379
Ending Balance at Jul. 01, 2018	2,433,981	$ 47,082	570,037	2,311,712	(306,420)	$ (188,430)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	56,524			56,524
Cash dividends	(15,588)			(15,588)
Other comprehensive income (loss)	17,253				17,253
Shares issued under compensation plans (in shares)		(110)				(2)
Shares issued under compensation plans	14,598	$ 110	14,331			$ 157
Deferred compensation (in shares)						(2)
Deferred compensation	311		163			$ 148
Settlements of warrants (in shares)						(140)
Settlements of warrants	(14)		(19,212)			$ 19,198
Ending Balance (in shares) at Sep. 30, 2018		47,192				1,235
Ending Balance at Sep. 30, 2018	2,507,065	$ 47,192	565,319	2,352,648	(289,167)	$ (168,927)
Beginning Balance (in shares) at Dec. 31, 2018		47,248				1,232
Beginning Balance at Dec. 31, 2018	2,539,978	$ 47,248	574,761	2,427,599	(341,085)	$ (168,545)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	40,897			40,897
Cash dividends	(15,650)			(15,650)
Other comprehensive income (loss)	396				396
Shares issued under compensation plans (in shares)		(75)				(40)
Shares issued under compensation plans	5,198	$ 75	3,094			$ 2,029
Deferred compensation (in shares)						(4)
Deferred compensation	380		127			$ 253
Ending Balance (in shares) at Mar. 31, 2019		47,323				1,188
Ending Balance at Mar. 31, 2019	2,569,878	$ 47,323	577,982	2,451,525	(340,689)	$ (166,263)
Beginning Balance (in shares) at Dec. 31, 2018		47,248				1,232
Beginning Balance at Dec. 31, 2018	2,539,978	$ 47,248	574,761	2,427,599	(341,085)	$ (168,545)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	353,201
Other comprehensive income (loss)	(23,416)
Ending Balance (in shares) at Sep. 29, 2019		47,463				1,184
Ending Balance at Sep. 29, 2019	2,852,976	$ 47,463	603,634	2,732,408	(364,501)	$ (166,028)
Beginning Balance (in shares) at Mar. 31, 2019		47,323				1,188
Beginning Balance at Mar. 31, 2019	2,569,878	$ 47,323	577,982	2,451,525	(340,689)	$ (166,263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	83,375			83,375
Cash dividends	(15,697)			(15,697)
Other comprehensive income (loss)	14,782				14,782
Shares issued under compensation plans (in shares)		(77)				(2)
Shares issued under compensation plans	12,506	$ 77	12,252			$ 177
Ending Balance (in shares) at Jun. 30, 2019		47,400				1,186
Ending Balance at Jun. 30, 2019	2,664,844	$ 47,400	590,234	2,519,203	(325,907)	$ (166,086)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	228,929			228,929
Cash dividends	(15,724)			(15,724)
Other comprehensive income (loss)	(38,594)				(38,594)
Shares issued under compensation plans (in shares)		(63)				(2)
Shares issued under compensation plans	13,521	$ 63	13,400			$ 58
Ending Balance (in shares) at Sep. 29, 2019		47,463				1,184
Ending Balance at Sep. 29, 2019	$ 2,852,976	$ 47,463	$ 603,634	$ 2,732,408	$ (364,501)	$ (166,028)

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 0.34	$ 0.34	$ 0.34	$ 0.34

Basis of presentation

Basis of presentation	9 Months Ended
	Sep. 29, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Note 1 — Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our,” “Teleflex” and the “Company”) are prepared on the same basis as its annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of the financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for the form and content of presentation of financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year. In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. Therefore, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018.

Recently issued accounting stan

Recently issued accounting standards	9 Months Ended
	Sep. 29, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recently issued accounting standards	Recently issued accounting standards In February 2016, the FASB issued guidance that changes the requirements for accounting for leases. Under the new guidance, in connection with a lease as to which an entity is a lessee, the entity generally must recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under previous guidance, operating leases were not recognized on the balance sheet. The Company adopted the new standard on January 1, 2019 using a modified retrospective transition approach, which requires leases existing at, or entered into after, January 1, 2019 to be recognized and measured in the condensed consolidated balance sheet. The Company recognized additional net lease assets and lease liabilities of $105.3 million and $106.6 million, respectively, upon adoption of the guidance. The difference between the additional lease assets and lease liabilities was recorded as an adjustment to the Company's opening balance of retained earnings. Prior period amounts have not been adjusted and continue to reflect the Company's historical accounting. As permitted under the new guidance, the Company has made an accounting policy election not to apply the recognition provisions of the new guidance to short term leases (leases with a lease term of 12 months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, the Company will recognize the lease payments for short term leases on a straight-line basis over the lease term. In addition, the Company has elected to apply certain practical expedients available under the new guidance. As a result, and in connection with the transition to the new guidance, the Company did not reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, or (iii) initial direct costs for any existing leases. The Company applied the practical expedients described above to its entire lease portfolio at the January 1, 2019 adoption date. Furthermore, as permitted under the new guidance, the Company has made, as a practical expedient, an accounting policy election to not separate lease and non-lease components and instead will account for each separate lease component and the non-lease components associated with that lease component as a single lease component. Additional information and disclosures required by the new guidance are contained in Note 8. In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of federal tax legislation commonly referred to as the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance, which was effective January 1, 2019, permits reclassification of these amounts from accumulated other comprehensive income to retained earnings thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The Company elected not to reclassify stranded tax effects from accumulated other comprehensive income to retained earnings. In June 2016, the FASB issued new guidance that changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under current guidance, an entity reflects credit losses on financial assets measured on an amortized cost basis only when it is probable that losses have been incurred, generally considering only past events and current conditions in determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable forecasts. The main objective of the new guidance is to provide financial statement users with more useful information in making decisions about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The new guidance will be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the annual period in which the adoption is effective. The Company is currently evaluating the impact the guidance will have on its consolidated financial statements and related disclosures, but it is not expected to have a material effect on the consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Net revenues

Net revenues	9 Months Ended
	Sep. 29, 2019
Revenue from Contract with Customer [Abstract]
Net revenues	Net revenuesThe Company primarily generates revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with the Company’s customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when the Company’s products are shipped from the manufacturing or distribution facility. For the Company’s Original Equipment and Development Services ("OEM") segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and the Company has an enforceable right to payment to the extent that performance has been completed. The Company markets and sells products through its direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers such as pharmacies, which comprised 88%, 10% and 2% of consolidated net revenues, respectively, for the nine months ended September 29, 2019. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. The following table disaggregates revenue by global product category for the three and nine months ended September 29, 2019 and September 30, 2018. Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Dollars in thousands) Vascular access $ 148,681 $ 142,079 $ 446,225 $ 426,256 Anesthesia 87,123 87,531 253,098 261,764 Interventional 106,883 99,975 314,852 288,306 Surgical 92,621 89,908 274,911 266,046 Interventional urology 73,629 48,995 201,312 138,969 OEM 55,444 54,838 166,110 153,286 Other (1) 83,938 86,346 257,902 272,141 Net revenues (2) $ 648,319 $ 609,672 $ 1,914,410 $ 1,806,768 (1) Revenues in the "Other" category in the table above include revenues generated from sales of the Company’s respiratory and urology products (other than interventional urology products). For the three and nine months ended September 29, 2019, the Company reclassified its cardiac products from "Other" to "Interventional". The comparative prior year period has been restated to conform to the current period presentation.

Divestitures

Divestitures	9 Months Ended
	Sep. 29, 2019
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	DivestituresOn February 4, 2019, the Company sold substantially all of the assets related to its vein catheter reprocessing business for $12.6 million. The Company recognized a $2.7 million pre-tax gain on the sale of assets, which represents the excess of the $9.7 million fair value of consideration received over the carrying value of the assets sold. In connection with the sale, the purchaser of the assets issued a secured promissory note to the Company in the principal amount of $10.5 million. The purchaser's obligations under the notes are secured by a lien on substantially all of the purchaser's assets. The purchaser is obligated to repay the principal amount of the promissory note in annual installments of $2.1 million on each of the first five anniversaries of the date of sale. On the date of sale, the fair value of the promissory note was $7.6 million, which the Company calculated by applying a discount rate determined after taking into account the creditworthiness of the purchaser. As of September 29, 2019, the Company had $8.3 million in receivables related to the promissory note, of which $2.1 million and $6.2 million are included in accounts receivable, net and other assets, respectively, within the condensed consolidated balance sheet.

Restructuring and impairment ch

Restructuring and impairment charges (credits)	9 Months Ended
	Sep. 29, 2019
Restructuring and Related Activities [Abstract]
Restructuring and impairment charges (credits)	Restructuring and impairment charges The following tables provide information regarding restructuring and impairment charges recognized by the Company for the three and nine months ended September 29, 2019 and September 30, 2018: Three Months Ended September 29, 2019 Termination benefits Other costs (1) Total (Dollars in thousands) 2019 Footprint realignment plan $ 584 $ 38 $ 622 2018 Footprint realignment plan 315 74 389 Other restructuring programs (2) 7 250 257 Restructuring charges $ 906 $ 362 $ 1,268 Three Months Ended September 30, 2018 Termination benefits Other costs (1) Total (Dollars in thousands) 2018 Footprint realignment plan $ 1,119 $ 145 $ 1,264 Other restructuring programs (4) 468 232 700 Restructuring charges 1,587 377 1,964 Asset impairment charges — 17,245 17,245 Restructuring and impairment charges $ 1,587 $ 17,622 $ 19,209 Nine Months Ended September 29, 2019 Termination Benefits Other costs (1) Total (Dollars in thousands) 2019 Footprint realignment plan $ 13,100 $ 68 $ 13,168 2018 Footprint realignment plan (1,523) 782 (741) Other restructuring programs (2) 195 815 1,010 Restructuring charges 11,772 1,665 13,437 Asset impairment charges — 6,911 6,911 Restructuring and impairment charges $ 11,772 $ 8,576 $ 20,348 Nine Months Ended September 30, 2018 Termination Benefits Other costs (1) Total (Dollars in thousands) 2018 Footprint realignment plan $ 53,463 $ 275 $ 53,738 2016 Footprint realignment plan (3) 2,379 417 2,796 Other restructuring programs (4) 1,318 663 1,981 Restructuring charges 57,160 1,355 58,515 Asset impairment charges — 19,110 19,110 Restructuring and impairment charges $ 57,160 $ 20,465 $ 77,625 (1) Other restructuring costs include facility closure, contract termination and other exit costs. (2) Includes a restructuring program initiated in the third quarter 2019 that is designed to reduce costs and improve efficiencies through reorganizations within several businesses and certain corporate functions, th e Vascular Solutions integration program (initiated in 2017) and the 2016 and 2014 Footprint realignment plans. (3) The 2016 Footprint realignment plan involved the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. The program is substantially complete and the Company expects future restructuring expenses associated with the program, if any, to be immaterial. (4) Includes the Vascular Solutions integration program, the 2014 Footprint realignment plan and the EMEA restructuring program (initiated in 2017). 2019 Footprint Realignment Plan In February 2019, the Company initiated a restructuring plan primarily involving the relocation of certain manufacturing operations to existing lower-cost locations and related workforce reductions (the "2019 Footprint realignment plan"). These actions are expected to be substantially completed during 2022. The following table provides a summary of the Company’s estimates of restructuring and restructuring related charges by major type of expense associated with the 2019 Footprint realignment plan: Type of expense Total estimated amount expected to be incurred Termination benefits $19 million to $23 million Other exit costs (1) $1 million to $2 million Restructuring charges $20 million to $25 million Restructuring related charges (2) $36 million to $45 million Total restructuring and restructuring related charges $56 million to $70 million (1) Includes facility closure, employee relocation, equipment relocation and outplacement costs. (2) Restructuring related charges represent costs that are directly related to the 2019 Footprint realignment plan and principally constitute costs to transfer manufacturing operations to existing lower-cost locations, project management costs and accelerated depreciation. Most of these charges are expected to be recognized within cost of goods sold. In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2019 Footprint realignment plan of $1.9 million and $3.6 million, respectively, for the three and nine months ended September 29, 2019 within cost of goods sold. As of September 29, 2019, the Company has a restructuring reserve of $11.8 million in connection with this plan, all of which relate to termination benefits. 2018 Footprint Realignment Plan On May 1, 2018, the Company initiated a restructuring plan involving the relocation of certain European manufacturing operations to existing lower-cost locations, the outsourcing of certain of the Company’s European distribution operations and related workforce reductions (the “2018 Footprint realignment plan"). These actions are expected to be substantially completed by the end of 2024. The Company recorded restructuring related charges with respect to the 2018 Footprint realignment plan of $0.8 million and $2.1 million for the three and nine months ended September 29, 2019, respectively, and $1.8 million and $2.8 million for the three and nine months ended September 30, 2018, respectively. The restructuring related charges were included within cost of goods sold. The majority of the restructuring related charges in both periods constituted costs arising from the transfer of manufacturing operations to new locations. The Company estimates that it will incur aggregate pre-tax restructuring a nd restructuring related charges in connection with the 2018 Footprint realignment plan of approximately $102 million to $133 million, respectively. As of September 29, 2019, the Company has incurred aggregate restructuring charges in connection with the 2018 Footprint realignment plan of $54.3 million, principally related to termination benefits . In addition, as of September 29, 2019, the Company has incurred aggregate restructuring related charges of $6.2 million with respect to the 2018 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations to new locations. The restructuring related charges primarily were included in cost of goods sold. As of September 29, 2019, the Company has a restructuring reserve of $44.0 million in connection with this plan, all of which related to termination benefits. 2014 Footprint Realignment Plan In 2014, the Company initiated a restructuring plan (“the 2014 Footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed during 2021. The Company recorded restructuring related charges with respect to the 2014 Footprint realignment plan of $0.8 million and $2.1 million for the three and nine months ended September 29, 2019, respectively, and $0.8 million and $1.8 million for the three and nine months ended September 30, 2018, respectively. The majority of these restructuring related charges in both periods constituted costs arising from the transfer of manufacturing operations to new locations. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 Footprint realignment plan of $47 million to $52 million, respectively. As of September 29, 2019, the Company has incurred aggregate restructuring charges of $12.8 million in connection with the 2014 Footprint realignment plan, principally related to termination benefits . Additionally, as of September 29, 2019, the Company has incurred aggregate restructuring related charges of $31.2 million in connection with the 2014 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations from the existing locations to new locations. These restructuring related charges primarily were included in cost of goods sold. As of September 29, 2019, the Company has a restructuring reserve of $3.7 million in connection with the plan, all of which related to termination benefits.

Inventories, net

Inventories, net	9 Months Ended
	Sep. 29, 2019
Inventory Disclosure [Abstract]
Inventories, net	Inventories, net Inventories as of September 29, 2019 and December 31, 2018 consisted of the following: September 29, 2019 December 31, 2018 (Dollars in thousands) Raw materials $ 121,080 $ 111,105 Work-in-process 72,211 62,334 Finished goods 279,303 254,339 Inventories, net $ 472,594 $ 427,778

Goodwill and other intangible a

Goodwill and other intangible assets, net	9 Months Ended
	Sep. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets, net	Note 7 — Goodwill and other intangible assets, net The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the nine months ended September 29, 2019: Americas EMEA Asia OEM Total (Dollars in thousands) December 31, 2018 $ 1,549,534 $ 480,615 $ 211,547 $ 4,883 $ 2,246,579 Goodwill related to acquisitions 441 189 1,211 — 1,841 Currency translation adjustment (4,055) (11,667) (1,368) — (17,090) September 29, 2019 $ 1,545,920 $ 469,137 $ 211,390 $ 4,883 $ 2,231,330 The Company's gross carrying amount of, and accumulated amortization relating to, intangible assets as of September 29, 2019 and December 31, 2018 were as follows: Gross Carrying Amount Accumulated Amortization September 29, 2019 December 31, 2018 September 29, 2019 December 31, 2018 (Dollars in thousands) Customer relationships $ 1,011,462 $ 1,030,194 $ (354,140) $ (322,972) In-process research and development 27,432 28,457 — — Intellectual property 1,342,956 1,363,516 (379,332) (322,539) Distribution rights 23,274 23,465 (18,492) (17,860) Trade names 560,613 565,070 (46,878) (36,379) Non-compete agreements 22,215 23,004 (13,437) (8,904) $ 2,987,952 $ 3,033,706 $ (812,279) $ (708,654)

Leases

Leases	9 Months Ended
	Sep. 29, 2019
Leases [Abstract]
Leases	Leases The Company has operating leases for various types of properties, consisting of manufacturing plants, engineering and research centers, distribution warehouses, offices and other facilities, and equipment used in operations. Some leases provide the Company with an option, exercisable at the Company's sole discretion, to terminate the lease or extend the lease term for one Maturities of lease liabilities September 29, 2019 (Dollars in thousands) 2019 $ 6,254 2020 25,527 2021 23,183 2022 21,423 2023 17,511 2024 and thereafter 54,172 Total lease payments 148,070 Less: interest (23,544) Present value of lease liabilities $ 124,526 Supplemental information as of and for the nine months ended September 29, 2019 (dollars in thousands) Total lease liabilities (1) $ 124,526 Cash paid for amounts included in the measurement of lease liabilities within operating cash flows $ 19,520 Right of use assets obtained in exchange for operating lease obligations $ 34,632 Weighted average remaining lease term 7.4 years Weighted average discount rate 4.4 % (1) The current portion of the operating lease liabilities of $20.4 million is included in Other current liabilities. As of December 31, 2018, minimum lease payments under noncancellable operating leases were expected to be as follows: December 31, 2018 (Dollars in thousands) 2019 $ 25,294 2020 23,216 2021 21,419 2022 19,460 2023 17,403 2024 and thereafter 41,368

Borrowings

Borrowings	9 Months Ended
	Sep. 29, 2019
Debt Disclosure [Abstract]
Borrowings	Borrowings The Company's borrowings at September 29, 2019 and December 31, 2018 were as follows: September 29, 2019 December 31, 2018 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 3.55% at September 29, 2019, due 2024 $ 143,000 $ 293,000 Term loan facility, at a rate of 3.55% at September 29, 2019, due 2024 673,000 683,500 5.25% Senior Notes due 2024 250,000 250,000 4.875% Senior Notes due 2026 400,000 400,000 4.625% Senior Notes due 2027 500,000 500,000 Securitization program, at a rate of 2.78% at September 29, 2019 50,000 50,000 2,016,000 2,176,500 Less: Unamortized debt issuance costs (16,932) (17,675) 1,999,068 2,158,825 Current borrowings (50,000) (86,625) Long-term borrowings $ 1,949,068 $ 2,072,200 Credit Agreement On April 5, 2019, the Company amended and restated its existing credit agreement by entering into a Second Amended and Restated Credit Agreement (the "Credit Agreement"), which provides for a five-year revolving credit facility of $1.0 billion and a term loan facility of $700.0 million. The Company's obligations under the Credit Agreement are guaranteed (subject to certain exceptions and limitations) by substantially all of the material domestic subsidiaries of the Company. The obligations under the Credit Agreement are secured, subject to certain exceptions and limitations, by a lien on substantially all of the assets owned by the Company and each guarantor. The maturity date of the revolving credit facility and the term loan facility under the Credit Agreement is April 5, 2024. At the Company’s option, loans under the Credit Agreement will bear interest at a rate equal to adjusted LIBOR plus an applicable margin ranging from 1.250% to 2.00% or at an alternate base rate, which generally is defined as the highest of (i) the “Prime Rate” in the U.S. last quoted by The Wall Street Journal, (ii) 0.50% above the greater of the federal funds rate and the rate comprised of both overnight federal funds and overnight eurodollar borrowings and (iii) 1.00% above adjusted LIBOR for a one month interest period, plus in each case an applicable margin ranging from 0.125% to 1.00%, in each case subject to adjustments based on the Company’s consolidated total net leverage ratio. Overdue loans will bear interest at the rate otherwise applicable to such loans plus 2.00%. The Credit Agreement contains customary representations and warranties and covenants that, in each case, subject to certain exceptions, qualifications and thresholds, (a) place limitations on the Company and its subsidiaries regarding the incurrence of additional indebtedness, additional liens, fundamental changes, dispositions of property, investments and acquisitions, dividends and other restricted payments, transactions with affiliates, restrictive agreements, changes in lines of business and swap agreements, and (b) require the Company and its subsidiaries to comply with sanction laws and other laws and agreements, to deliver financial information and certain other information and give notice of certain events, to maintain their existence and good standing, to pay their other obligations, to permit the administrative agent and the lenders to inspect their books and property, to use the proceeds of the Credit Agreement only for certain permitted purposes and to provide collateral in the future. Subject to certain exceptions, the Company is required to maintain a maximum consolidated total net leverage ratio of 4.50 to 1.00. The Company is further required to maintain a minimum consolidated interest coverage ratio of 3.50 to 1.00.

Financial instruments

Financial instruments	9 Months Ended
	Sep. 29, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Financial instruments Foreign currency forward contracts The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage exposure related to foreign currency transactions. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. The Company enters into the non-designated foreign currency forward contracts for periods consistent with its currency translation exposures, which generally approximate one month. For the three and nine months ended September 29, 2019, the Company recognized losses of $1.9 million and $3.5 million, respectively, related to non-designated foreign currency forward contracts. For the three and nine months ended September 30, 2018, the Company recognized gains related to non-designated foreign currency forward contracts of $1.0 million and $0.3 million, respectively. The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of September 29, 2019 and December 31, 2018 was $115.6 million and $115.3 million, respectively. The total notional amount for all open non-designated foreign currency forward contracts as of September 29, 2019 and December 31, 2018 was $170.1 million and $125.9 million, respectively. All open foreign currency forward contracts as of September 29, 2019 have durations of 12 months or less. Cross-currency interest rate swaps On March 4, 2019, the Company entered into cross-currency swap agreements with five different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, the Company has notionally exchanged $250 million at an annual interest rate of 4.8750% for €219.2 million at an annual interest rate of 2.4595%. The swap agreements are designed as net investment hedges and expire on March 4, 2024. On October 4, 2018, the Company entered into cross-currency swap agreements with six different financial institution counterparties to hedge against the effect of variability in the U.S. dollar to euro exchange rate. Under the terms of the cross-currency swap agreements, the Company has notionally exchanged $500 million at an annual interest rate of 4.625% for €433.9 million at an annual interest rate of 1.942%. The swap agreements are designed as net investment hedges and expire on October 4, 2023. The swap agreements described above require an exchange of the notional amounts upon expiration or earlier termination of the agreements. We and the counterparties have agreed to effect the exchange through a net settlement. The cross-currency swaps are marked to market at each reporting date and any changes in fair value are recognized as a component of accumulated other comprehensive income (loss) ("AOCI"). For the three and nine months ended September 29, 2019, the Company recognized foreign exchange gains of $23.5 million and 29.4 million, respectively, within AOCI related to the cross-currency swaps. Balance sheet presentation The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of September 29, 2019 and December 31, 2018: September 29, 2019 December 31, 2018 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 998 $ 1,216 Non-designated foreign currency forward contracts 289 106 Cross-currency interest rate swap 26,754 14,728 Prepaid expenses and other current assets 28,041 16,050 Cross-currency interest rate swap 23,857 — Other assets 23,857 — Total asset derivatives $ 51,898 $ 16,050 Liability derivatives: Designated foreign currency forward contracts $ 795 $ 524 Non-designated foreign currency forward contracts 137 264 Other current liabilities 932 788 Cross-currency interest rate swap — 7,793 Other liabilities — 7,793 Total liability derivatives $ 932 $ 8,581 See Note 12 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from AOCI to expense (income), net of tax. There was no ineffectiveness related to the Company’s cash flow hedges during the three and nine months ended September 29, 2019 and September 30, 2018. Trade receivables

Fair value measurement

Fair value measurement	9 Months Ended
	Sep. 29, 2019
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement For a description of the fair value hierarchy, see Note 11 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2018. The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of September 29, 2019 and December 31, 2018: Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 10,168 $ 10,168 $ — $ — Derivative assets 51,898 — 51,898 — Derivative liabilities 932 — 932 — Contingent consideration liabilities 206,880 — — 206,880 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,671 $ 8,671 $ — $ — Derivative assets 16,050 — 16,050 — Derivative liabilities 8,581 — 8,581 — Contingent consideration liabilities 304,248 — — 304,248 There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the nine months ended September 29, 2019. Valuation Techniques The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts and cross-currency interest rate swap agreements. The Company uses foreign currency forward contracts and cross-currency interest rate swap agreements to manage foreign currency transaction exposure, exposure to foreign currency denominated monetary assets and liabilities and exposure to the effect of variability in the U.S. dollar to euro exchange rate. The Company measures the fair value of the foreign currency forward and cross-currency swap agreements by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties. The Company’s financial liabilities valued based upon Level 3 inputs (inputs that are not observable in the market) are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions, which are discussed immediately below. Contingent consideration Contingent consideration liabilities, which primarily consist of payment obligations that are contingent upon the achievement of revenue-based goals, but also can be based on other milestones such as regulatory approvals, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates. The Company determines the fair value of the contingent consideration liabilities using a Monte Carlo simulation (which involves a simulation of future revenues during the earn out-period using management's best estimates) or a probability-weighted discounted cash flow analysis. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect. The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration. Contingent Consideration Liability Valuation Technique Unobservable Input Range Milestone-based payments Discounted cash flow Discount rate 3.1% - 3.7% Projected year of payment 2020 - 2023 Revenue-based payments Monte Carlo simulation Revenue volatility 18.6% - 23.9% Risk free rate Cost of debt structure Projected year of payment 2020 - 2022 Discounted cash flow Discount rate 10.0% Projected year of payment 2019 - 2029 The following table provides information regarding changes in the Company's contingent consideration liabilities during the nine months ended September 29, 2019: Contingent consideration 2019 (Dollars in thousands) Balance - December 31, 2018 $ 304,248 Payments (1) (138,098) Revaluations 40,894 Translation adjustment (164) Balance - September 29, 2019 $ 206,880

Shareholders' equity

Shareholders' equity	9 Months Ended
	Sep. 29, 2019
Equity [Abstract]
Shareholders' equity	Shareholders’ equity Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Shares in thousands) Basic 46,248 45,851 46,156 45,587 Dilutive effect of share-based awards 928 919 895 1,007 Dilutive effect of convertible warrants — 45 — 191 Diluted 47,176 46,815 47,051 46,785 The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 0.1 million for the three and nine months ended September 29, 2019 and 0.7 million for the three and nine months ended September 30, 2018. The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended September 29, 2019 and September 30, 2018: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2018 $ 807 $ (131,380) $ (210,512) $ (341,085) Other comprehensive income (loss) before reclassifications 646 215 (27,562) (26,701) Amounts reclassified from accumulated other comprehensive income (748) 4,033 — 3,285 Net current-period other comprehensive (loss) income (102) 4,248 (27,562) (23,416) Balance as of September 29, 2019 $ 705 $ (127,132) $ (238,074) $ (364,501) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2017 $ 340 $ (138,808) $ (126,623) $ (265,091) Other comprehensive income (loss) before reclassifications 2,816 127 (30,130) (27,187) Amounts reclassified from accumulated other comprehensive loss (873) 3,984 — 3,111 Net current-period other comprehensive income (loss) 1,943 4,111 (30,130) (24,076) Balance as of September 30, 2018 $ 2,283 $ (134,697) $ (156,753) $ (289,167) The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and nine months ended September 29, 2019 and September 30, 2018: Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (523) $ (87) $ (888) $ (1,038) Total before tax (523) (87) (888) (1,038) Taxes (benefit) 46 25 140 165 Net of tax $ (477) $ (62) $ (748) $ (873) Losses (gains) on cross-currency swaps (net investment hedge): Interest expense $ (5,021) $ — $ (13,820) $ — Total before tax (5,021) — (13,820) — Tax expense $ 1,164 — 3,204 — Net of tax (3,857) $ — $ (10,616) $ — Amortization of pension and other postretirement benefit items (1) : Actuarial losses $ 1,716 $ 1,640 $ 5,194 $ 5,120 Prior-service costs 21 24 65 71 Total before tax 1,737 1,664 5,259 5,191 Tax benefit (405) (388) (1,226) (1,207) Net of tax $ 1,332 $ 1,276 $ 4,033 $ 3,984 Total reclassifications, net of tax $ (3,002) $ 1,214 $ (7,331) $ 3,111 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans.

Taxes on income from continuing

Taxes on income from continuing operations	9 Months Ended
	Sep. 29, 2019
Income Tax Disclosure [Abstract]
Taxes on income from continuing operations	Taxes on income from continuing operations Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Effective income tax rate (132.3)% (2.3)% (48.4)% 11.8% The effective income tax rate for the three and nine months ended September 29, 2019 was (132.3)% and (48.4)%, respectively, and (2.3)% and 11.8%, respectively, for the three and nine months ended September 30, 2018. The effective income tax rates for the three and nine months ended September 29, 2019 reflect a discrete tax benefit of $129 million resulting from a non-U.S. legal entity restructuring that eliminated the requirement to provide for foreign withholding taxes on the future repatriation of certain non-permanently reinvested earnings. T he effective tax rates for the three and nine months ended September 30, 2018 include a tax benefit associated with asset impairment charges. In addition, the income tax rate for the nine months ended September 30, 2018 reflects non-deductible termination benefits and other costs incurred in connection with the 2018 Footprint realignment plan as described in Note 5.

Commitments and contingent liab

Commitments and contingent liabilities	9 Months Ended
	Sep. 29, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Commitments and contingent liabilities Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At September 29, 2019, the Company has recorded $0.9 million and $6.3 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of September 29, 2019. The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 10-15 years. Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of September 29, 2019, the Company has recorded accrued liabilities of $0.2 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various tax authorities. As of September 29, 2019, the most significant tax examination in process is in Germany. The Company may establish reserves with respect to its uncertain tax positions, after which it adjusts the reserves to address developments with respect to its uncertain tax positions, including developments in this tax examination. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results.

Segment information

Segment information	9 Months Ended
	Sep. 29, 2019
Segment Reporting [Abstract]
Segment information	Segment informationDuring the first quarter 2019, the chief operating decision maker, or CODM, (the Company's Chief Executive Officer) changed the manner in which he reviews financial information for purposes of assessing business performance and allocating resources by focusing on the geographic location of all non-OEM operations. As a result, the Company changed its segment presentation. Specifically, the Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Interventional Urology North America, Respiratory North America and Latin America operating segments were combined into a new Americas segment. The Company now has four segments: Americas, EMEA (Europe, Middle East and Africa), Asia and OEM. All prior comparative periods presented have been restated to reflect these changes. The following tables present the Company’s segment results for the three and nine months ended September 29, 2019 and September 30, 2018: Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Dollars in thousands) Americas $ 374,493 $ 338,749 $ 1,092,321 $ 993,455 EMEA 140,518 139,541 442,110 452,826 Asia 77,864 76,544 213,869 207,201 OEM 55,444 54,838 166,110 153,286 Net revenues $ 648,319 $ 609,672 $ 1,914,410 $ 1,806,768 Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Dollars in thousands) Americas $ 81,405 $ 68,559 $ 229,513 $ 174,764 EMEA 21,820 21,916 69,670 80,221 Asia 21,460 20,834 50,699 54,948 OEM 16,008 15,049 43,213 37,617 Total segment operating profit (1) 140,693 126,358 393,095 347,550 Unallocated expenses (2) (23,072) (44,253) (92,773) (145,112) Income from continuing operations before interest and taxes $ 117,621 $ 82,105 $ 300,322 $ 202,438 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

Condensed consolidating guarant

Condensed consolidating guarantor financial information	9 Months Ended
	Sep. 29, 2019
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed consolidating guarantor financial information	Condensed consolidating guarantor financial information The Company’s $250 million principal amount of 5.25% Senior Notes due 2024 (the “2024 Notes”), $400 million principal amount of 4.875% Senior Notes due 2026 (the “2026 Notes”) and $500 million principal amount of 4.625% Senior Notes due 2027 (the “2027 Notes," and collectively with the 2024 Notes and the 2026 Notes, the "Senior Notes") are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the Senior Notes is guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The 2024 Notes, 2026 Notes and 2027 Notes are guaranteed by the same Guarantor Subsidiaries. The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three and nine months ended September 29, 2019 and September 30, 2018, condensed consolidating balance sheets as of September 29, 2019 and December 31, 2018 and condensed consolidating statements of cash flows for the nine months ended September 29, 2019 and September 30, 2018, provide consolidated information for: a. Parent Company, the issuer of the guaranteed obligations; b. Guarantor Subsidiaries, on a combined basis; c. Non-Guarantor Subsidiaries (i.e., those subsidiaries of the Parent Company that have not guaranteed d. Parent Company and its subsidiaries on a consolidated basis. In connection with the Company's entry into the Credit Agreement on April 5, 2019 (as described in Note 9), a subsidiary of the Company (the "Released Subsidiary") that was a guarantor of Parent Company’s obligations under the previously outstanding credit agreement and under the Senior Notes was removed as a guarantor of Parent Company’s obligations under the Credit Agreement. Under the indentures governing the Senior Notes, the removal of the Released Subsidiary as a guarantor under the Credit Agreement automatically resulted in the release of the Released Subsidiary from its guarantees of the Senior Notes. Therefore, as of the date of the Credit Agreement, the Released Subsidiary is no longer a Guarantor Subsidiary. The condensed consolidating statements of income and comprehensive income for the three and nine months ended September 30, 2018, the condensed consolidating balance sheet as of December 31, 2018 and the condensed consolidating statement of cash flows for the nine months ended September 30, 2018 have been restated to exclude the Released Subsidiary from the information relating to the Guarantor Subsidiaries and to include the Released Subsidiary in the information relating to Non-Guarantor Subsidiaries. The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidating financial information, except for the use of the equity method of accounting to reflect ownership interests in subsidiaries, which are eliminated upon consolidation. Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries. TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended September 29, 2019 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 449,753 $ 338,889 $ (140,323) $ 648,319 Cost of goods sold — 290,466 112,090 (129,917) 272,639 Gross profit — 159,287 226,799 (10,406) 375,680 Selling, general and administrative expenses 14,919 140,053 75,421 (497) 229,896 Research and development expenses 334 20,321 7,329 — 27,984 Restructuring and impairment charges — 661 607 — 1,268 Gain on sale of assets — — (1,089) — (1,089) (Loss) income from continuing operations before interest and taxes (15,253) (1,748) 144,531 (9,909) 117,621 Interest, net 25,367 (20,911) 14,619 — 19,075 (Loss) income from continuing operations before taxes (40,620) 19,163 129,912 (9,909) 98,546 (Benefit) taxes on (loss) income from continuing operations (13,374) 4,393 (119,578) (1,824) (130,383) Equity in net income of consolidated subsidiaries 256,175 229,630 — (485,805) — Income from continuing operations 228,929 244,400 249,490 (493,890) 228,929 Operating loss from discontinued operations (9) — — — (9) Tax benefit on loss from discontinued operations (9) — — — (9) Income from discontinued operations — — — — — Net income 228,929 244,400 249,490 (493,890) 228,929 Other comprehensive income (38,594) (58,995) (62,882) 121,877 (38,594) Comprehensive income $ 190,335 $ 185,405 $ 186,608 $ (372,013) $ 190,335 Three Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed Consolidated (Dollars in thousands) Net revenues $ — $ 398,961 $ 322,010 $ (111,299) $ 609,672 Cost of goods sold — 232,209 146,301 (111,411) 267,099 Gross profit — 166,752 175,709 112 342,573 Selling, general and administrative expenses 11,347 130,769 72,800 (22) 214,894 Research and development expenses 378 19,482 6,505 — 26,365 Restructuring and impairment charges — 17,128 2,081 — 19,209 (Loss) income from continuing operations before interest and taxes (11,725) (627) 94,323 134 82,105 Interest, net 25,191 (15,391) 17,051 — 26,851 (Loss) income from continuing operations before taxes (36,916) 14,764 77,272 134 55,254 (Benefit) taxes on (loss) income from continuing operations (13,449) 1,765 10,385 13 (1,286) Equity in net income of consolidated subsidiaries 80,007 56,818 372 (137,197) — Income from continuing operations 56,540 69,817 67,259 (137,076) 56,540 Operating loss from discontinued operations (83) — — — (83) Tax benefit on loss from discontinued operations (67) — — — (67) Income from discontinued operations (16) — — — (16) Net income 56,524 69,817 67,259 (137,076) 56,524 Other comprehensive loss 17,253 14,107 16,947 (31,054) 17,253 Comprehensive income $ 73,777 $ 83,924 $ 84,206 $ (168,130) $ 73,777 Nine Months Ended September 29, 2019 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 1,304,385 $ 987,478 $ (377,453) $ 1,914,410 Cost of goods sold — 769,639 411,370 (359,945) 821,064 Gross profit — 534,746 576,108 (17,508) 1,093,346 Selling, general and administrative expenses 45,398 413,380 235,402 (405) 693,775 Research and development expenses 1,414 60,773 20,542 — 82,729 Restructuring and impairment charges — 6,742 13,606 — 20,348 Gain on sale of assets — — (3,828) — (3,828) (Loss) income from continuing operations before interest and taxes (46,812) 53,851 310,386 (17,103) 300,322 Interest, net 58,782 (42,756) 45,688 — 61,714 (Loss) income from continuing operations before taxes (105,594) 96,607 264,698 (17,103) 238,608 (Benefit) taxes on (loss) income from continuing operations (41,765) 31,643 (102,388) (3,057) (115,567) Equity in net income of consolidated subsidiaries 418,004 330,627 — (748,631) — Income from continuing operations 354,175 395,591 367,086 (762,677) 354,175 Operating loss from discontinued operations (1,291) — — — (1,291) Tax benefit on loss from discontinued operations (317) — — — (317) Loss from discontinued operations (974) — — — (974) Net income 353,201 395,591 367,086 (762,677) 353,201 Other comprehensive income (23,416) (43,389) (48,419) 91,808 (23,416) Comprehensive income $ 329,785 $ 352,202 $ 318,667 $ (670,869) $ 329,785 Nine Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 1,169,684 $ 968,298 $ (331,214) $ 1,806,768 Cost of goods sold — 681,300 431,841 (324,994) 788,147 Gross profit — 488,384 536,457 (6,220) 1,018,621 Selling, general and administrative expenses 32,958 400,987 226,555 (352) 660,148 Research and development expenses 1,094 57,668 19,648 — 78,410 Restructuring and impairment charges — 20,581 57,044 — 77,625 (Loss) income from continuing operations before interest and taxes (34,052) 9,148 233,210 (5,868) 202,438 Interest, net 72,120 (41,406) 48,273 — 78,987 (Loss) income from continuing operations before taxes (106,172) 50,554 184,937 (5,868) 123,451 (Benefit) taxes on (loss) income from continuing operations (39,859) 23,233 32,248 (1,090) 14,532 Equity in net income of consolidated subsidiaries 176,511 135,425 1,007 (312,943) — Income from continuing operations 110,198 162,746 153,696 (317,721) 108,919 Operating (loss) income from discontinued operations (33) — 1,279 — 1,246 Tax benefit on income (loss) from discontinued operations (47) — — — (47) Income from discontinued operations 14 — 1,279 — 1,293 Net income 110,212 162,746 154,975 (317,721) 110,212 Other comprehensive loss (24,076) (30,691) (26,551) 57,242 (24,076) Comprehensive income $ 86,136 $ 132,055 $ 128,424 $ (260,479) $ 86,136 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS September 29, 2019 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 34,196 $ 518 $ 222,830 $ — $ 257,544 Accounts receivable, net 3,228 69,322 318,375 5,738 396,663 Accounts receivable from consolidated subsidiaries 33,739 469,533 511,784 (1,015,056) — Inventories, net — 296,136 224,660 (48,202) 472,594 Prepaid expenses and other current assets 40,513 10,387 26,518 4,113 81,531 Prepaid taxes 19,518 — 9,760 — 29,278 Total current assets 131,194 845,896 1,313,927 (1,053,407) 1,237,610 Property, plant and equipment, net 2,889 246,496 180,183 — 429,568 Operating lease assets 13,136 68,830 33,227 — 115,193 Goodwill — 1,255,976 975,354 — 2,231,330 Intangibles assets, net 75 1,214,148 961,450 — 2,175,673 Investments in affiliates 5,824,869 2,138,760 924,448 (8,888,077) — Deferred tax assets 6,850 — 5,298 (9,196) 2,952 Notes receivable and other amounts due from consolidated subsidiaries 1,959,149 3,407,412 287,571 (5,654,132) — Other assets 42,666 12,017 10,173 — 64,856 Total assets $ 7,980,828 $ 9,189,535 $ 4,691,631 $ (15,604,812) $ 6,257,182 LIABILITIES AND EQUITY Current liabilities Current borrowings $ — $ — $ 50,000 $ — $ 50,000 Accounts payable 3,004 61,106 36,520 — 100,630 Accounts payable to consolidated subsidiaries 284,386 428,967 301,703 (1,015,056) — Accrued expenses 6,287 33,398 51,884 — 91,569 Current portion of contingent consideration — 124,789 10,379 — 135,168 Payroll and benefit-related liabilities 19,772 35,171 44,888 — 99,831 Accrued interest 19,658 — 28 — 19,686 Income taxes payable — — 6,356 (3,057) 3,299 Other current liabilities 4,049 14,849 11,282 — 30,180 Total current liabilities 337,156 698,280 513,040 (1,018,113) 530,363 Long-term borrowings 1,949,068 — — — 1,949,068 Deferred tax liabilities — 345,670 132,471 (9,196) 468,945 Pension and postretirement benefit liabilities 30,594 25,887 15,535 — 72,016 Noncurrent liability for uncertain tax positions 1,162 7,382 2,540 — 11,084 Notes payable and other amounts due to consolidated subsidiaries 2,673,870 1,860,819 1,119,443 (5,654,132) — Noncurrent contingent consideration — 44,137 27,575 — 71,712 Noncurrent operating lease liabilities 10,616 68,167 25,353 — 104,136 Other liabilities 125,386 9,619 61,877 — 196,882 Total liabilities 5,127,852 3,059,961 1,897,834 (6,681,441) 3,404,206 Total shareholders' equity 2,852,976 6,129,574 2,793,797 (8,923,371) 2,852,976 Total liabilities and shareholders' equity $ 7,980,828 $ 9,189,535 $ 4,691,631 $ (15,604,812) $ 6,257,182 December 31, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 49,523 $ 1,701 $ 305,937 $ — $ 357,161 Accounts receivable, net 5,885 54,013 301,054 5,334 366,286 Accounts receivable from consolidated subsidiaries 32,036 1,122,107 366,033 (1,520,176) — Inventories, net — 266,073 192,659 (30,954) 427,778 Prepaid expenses and other current assets 30,458 9,673 28,237 4,113 72,481 Prepaid taxes 7,029 — 5,434 — 12,463 Total current assets 124,931 1,453,567 1,199,354 (1,541,683) 1,236,169 Property, plant and equipment, net 3,385 253,037 176,344 — 432,766 Goodwill — 1,254,848 991,731 — 2,246,579 Intangibles assets, net 90 1,277,462 1,047,500 — 2,325,052 Investments in affiliates 5,984,566 1,625,464 837,899 (8,447,929) — Deferred tax assets — — 4,822 (2,376) 2,446 Notes receivable and other amounts due from consolidated subsidiaries 2,337,737 3,347,815 13,242 (5,698,794) — Other assets 17,180 5,776 12,023 — 34,979 Total assets $ 8,467,889 $ 9,217,969 $ 4,282,915 $ (15,690,782) $ 6,277,991 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,625 $ — $ 50,000 $ — $ 86,625 Accounts payable 3,448 62,764 40,497 — 106,709 Accounts payable to consolidated subsidiaries 1,058,008 292,093 170,075 (1,520,176) — Accrued expenses 5,659 41,873 50,019 — 97,551 Current portion of contingent consideration — 106,514 30,363 — 136,877 Payroll and benefit-related liabilities 17,156 44,982 42,532 — 104,670 Accrued interest 5,995 — 36 — 6,031 Income taxes payable — — 5,943 — 5,943 Other current liabilities 843 34,916 2,291 — 38,050 Total current liabilities 1,127,734 583,142 391,756 (1,520,176) 582,456 Long-term borrowings 2,072,200 — — — 2,072,200 Deferred tax liabilities 87,671 257,522 265,404 (2,376) 608,221 Pension and postretirement benefit liabilities 49,290 27,454 16,170 — 92,914 Noncurrent liability for uncertain tax positions 801 7,212 2,705 — 10,718 Notes payable and other amounts due to consolidated subsidiaries 2,451,784 2,222,580 1,024,430 (5,698,794) — Noncurrent contingent consideration — 131,563 35,807 — 167,370 Other liabilities 138,431 8,204 57,499 204,134 Total liabilities 5,927,911 3,237,677 1,793,771 (7,221,346) 3,738,013 Total shareholders' equity 2,539,978 5,980,292 2,489,144 (8,469,436) 2,539,978 Total liabilities and shareholders' equity $ 8,467,889 $ 9,217,969 $ 4,282,915 $ (15,690,782) $ 6,277,991 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Nine Months Ended September 29, 2019 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (72,369) $ 342,912 $ 272,115 $ (253,491) $ 289,167 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (460) (57,131) (26,206) — (83,797) Proceeds from sale of assets and investments 2,362 2,046 1,089 (2,362) 3,135 Payments for businesses and intangibles acquired, net of cash acquired — (1,025) (240) — (1,265) Net interest proceeds on swaps designated as net investment hedges 8,330 — — — 8,330 Investments in affiliates — (146) — 146 — Net cash provided by (used in) investing activities from continuing operations 10,232 (56,256) (25,357) (2,216) (73,597) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 25,000 — — — 25,000 Reduction in borrowings (185,500) — — — (185,500) Debt extinguishment, issuance and amendment fees (4,964) — — — (4,964) Net proceeds from share based compensation plans and the related tax impacts 14,014 — — — 14,014 Payments for contingent consideration — (15,122) (96,884) — (112,006) Proceeds from issuance of shares — — 146 (146) — Dividends paid (47,071) — — — (47,071) Intercompany transactions 242,049 (272,773) 28,362 2,362 — Intercompany dividends paid — — (253,491) 253,491 — Net cash provided by (used in) financing activities from continuing operations 43,528 (287,895) (321,867) 255,707 (310,527) Cash flows from discontinued operations: Net cash provided by (used in) operating activities 3,282 — (631) — 2,651 Net cash provided by (used in) discontinued operations 3,282 — (631) — 2,651 Effect of exchange rate changes on cash and cash equivalents — — (7,311) — (7,311) Net (decrease) increase in cash and cash equivalents (15,327) (1,239) (83,051) — (99,617) Cash and cash equivalents at the beginning of the period 49,523 1,757 305,881 — 357,161 Cash and cash equivalents at the end of the period $ 34,196 $ 518 $ 222,830 $ — $ 257,544 Nine Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (202,209) $ 321,389 $ 329,390 $ (145,626) $ 302,944 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (1,524) (23,686) (30,541) — (55,751) Proceeds from sale of assets 28,239 — — (28,239) — Payments for businesses and intangibles acquired, net of cash acquired (100) — (22,450) — (22,550) Net cash provided by (used in) investing activities from continuing operations 26,615 (23,686) (52,991) (28,239) (78,301) Cash flows from financing activities of continuing operations: Reduction in borrowings (98,500) — — — (98,500) Debt extinguishment, issuance and amendment fees (188) — — — (188) Net proceeds from share based compensation plans and the related tax impacts 18,666 — — — 18,666 Payments for contingent consideration — (10,748) (62,404) — (73,152) Dividends paid (46,526) — — — (46,526) Intercompany transactions 312,806 (294,600) (46,445) 28,239 — Intercompany dividends paid — — (145,626) 145,626 — Net cash provided by (used in) financing activities from continuing operations 186,258 (305,348) (254,475) 173,865 (199,700) Cash flows from discontinued operations: Net cash used in operating activities (701) — — — (701) Net cash used in discontinued operations (701) — — — (701) Effect of exchange rate changes on cash and cash equivalents — — (1,524) — (1,524) Net increase (decrease) in cash and cash equivalents 9,963 (7,645) 20,400 — 22,718 Cash and cash equivalents at the beginning of the period 37,803 8,933 286,822 — 333,558 Cash and cash equivalents at the end of the period $ 47,766 $ 1,288 $ 307,222 $ — $ 356,276

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 29, 2019
Subsequent Events [Abstract]
Subsequent event	Subsequent event Redemption of 5.25% Senior Notes due 2024 On October 31, 2019, the Company issued a notice of redemption to holders of its outstanding $250 million aggregate principal amount of 5.25% Senior Notes due 2024 (the “2024 Notes”). Pursuant to the notice of redemption, the 2024 Notes will be redeemed on November 15, 2019 (the “Redemption Date”) at a redemption price equal to 102.625% of the principal amount of the 2024 Notes plus accrued and unpaid interest up to, but not including, the Redemption Date (the “Redemption Price”). The notice of redemption provides that the redemption is subject to the condition that the Company is able to borrow funds under its revolving credit agreement on the Redemption Date in an amount sufficient to pay the aggregate Redemption Price. The Company anticipates it will recognize a loss on extinguishment of debt of $8.8 million in the fourth quarter of 2019 as a result of the redemption of the 2024 Notes.

Recently issued accounting st_2

Recently issued accounting standards (Policies)	9 Months Ended
	Sep. 29, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recently issued accounting standards	Recently issued accounting standards In February 2016, the FASB issued guidance that changes the requirements for accounting for leases. Under the new guidance, in connection with a lease as to which an entity is a lessee, the entity generally must recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under previous guidance, operating leases were not recognized on the balance sheet. The Company adopted the new standard on January 1, 2019 using a modified retrospective transition approach, which requires leases existing at, or entered into after, January 1, 2019 to be recognized and measured in the condensed consolidated balance sheet. The Company recognized additional net lease assets and lease liabilities of $105.3 million and $106.6 million, respectively, upon adoption of the guidance. The difference between the additional lease assets and lease liabilities was recorded as an adjustment to the Company's opening balance of retained earnings. Prior period amounts have not been adjusted and continue to reflect the Company's historical accounting. As permitted under the new guidance, the Company has made an accounting policy election not to apply the recognition provisions of the new guidance to short term leases (leases with a lease term of 12 months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, the Company will recognize the lease payments for short term leases on a straight-line basis over the lease term. In addition, the Company has elected to apply certain practical expedients available under the new guidance. As a result, and in connection with the transition to the new guidance, the Company did not reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, or (iii) initial direct costs for any existing leases. The Company applied the practical expedients described above to its entire lease portfolio at the January 1, 2019 adoption date. Furthermore, as permitted under the new guidance, the Company has made, as a practical expedient, an accounting policy election to not separate lease and non-lease components and instead will account for each separate lease component and the non-lease components associated with that lease component as a single lease component. Additional information and disclosures required by the new guidance are contained in Note 8. In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of federal tax legislation commonly referred to as the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance, which was effective January 1, 2019, permits reclassification of these amounts from accumulated other comprehensive income to retained earnings thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The Company elected not to reclassify stranded tax effects from accumulated other comprehensive income to retained earnings. In June 2016, the FASB issued new guidance that changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under current guidance, an entity reflects credit losses on financial assets measured on an amortized cost basis only when it is probable that losses have been incurred, generally considering only past events and current conditions in determining incurred loss. The new guidance requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset, based not only on historical experience and current conditions, but also on reasonable forecasts. The main objective of the new guidance is to provide financial statement users with more useful information in making decisions about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. The new guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted. The new guidance will be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the annual period in which the adoption is effective. The Company is currently evaluating the impact the guidance will have on its consolidated financial statements and related disclosures, but it is not expected to have a material effect on the consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Net revenues (Tables)

Net revenues (Tables)	9 Months Ended
	Sep. 29, 2019
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The following table disaggregates revenue by global product category for the three and nine months ended September 29, 2019 and September 30, 2018. Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Dollars in thousands) Vascular access $ 148,681 $ 142,079 $ 446,225 $ 426,256 Anesthesia 87,123 87,531 253,098 261,764 Interventional 106,883 99,975 314,852 288,306 Surgical 92,621 89,908 274,911 266,046 Interventional urology 73,629 48,995 201,312 138,969 OEM 55,444 54,838 166,110 153,286 Other (1) 83,938 86,346 257,902 272,141 Net revenues (2) $ 648,319 $ 609,672 $ 1,914,410 $ 1,806,768 (1) Revenues in the "Other" category in the table above include revenues generated from sales of the Company’s respiratory and urology products (other than interventional urology products). For the three and nine months ended September 29, 2019, the Company reclassified its cardiac products from "Other" to "Interventional". The comparative prior year period has been restated to conform to the current period presentation.

Restructuring and impairment _2

Restructuring and impairment charges (credits) (Tables)	9 Months Ended
	Sep. 29, 2019
Restructuring and Related Activities [Abstract]
Restructuring and Other Impairment Charges	The following tables provide information regarding restructuring and impairment charges recognized by the Company for the three and nine months ended September 29, 2019 and September 30, 2018: Three Months Ended September 29, 2019 Termination benefits Other costs (1) Total (Dollars in thousands) 2019 Footprint realignment plan $ 584 $ 38 $ 622 2018 Footprint realignment plan 315 74 389 Other restructuring programs (2) 7 250 257 Restructuring charges $ 906 $ 362 $ 1,268 Three Months Ended September 30, 2018 Termination benefits Other costs (1) Total (Dollars in thousands) 2018 Footprint realignment plan $ 1,119 $ 145 $ 1,264 Other restructuring programs (4) 468 232 700 Restructuring charges 1,587 377 1,964 Asset impairment charges — 17,245 17,245 Restructuring and impairment charges $ 1,587 $ 17,622 $ 19,209 Nine Months Ended September 29, 2019 Termination Benefits Other costs (1) Total (Dollars in thousands) 2019 Footprint realignment plan $ 13,100 $ 68 $ 13,168 2018 Footprint realignment plan (1,523) 782 (741) Other restructuring programs (2) 195 815 1,010 Restructuring charges 11,772 1,665 13,437 Asset impairment charges — 6,911 6,911 Restructuring and impairment charges $ 11,772 $ 8,576 $ 20,348 Nine Months Ended September 30, 2018 Termination Benefits Other costs (1) Total (Dollars in thousands) 2018 Footprint realignment plan $ 53,463 $ 275 $ 53,738 2016 Footprint realignment plan (3) 2,379 417 2,796 Other restructuring programs (4) 1,318 663 1,981 Restructuring charges 57,160 1,355 58,515 Asset impairment charges — 19,110 19,110 Restructuring and impairment charges $ 57,160 $ 20,465 $ 77,625 (1) Other restructuring costs include facility closure, contract termination and other exit costs. (2) Includes a restructuring program initiated in the third quarter 2019 that is designed to reduce costs and improve efficiencies through reorganizations within several businesses and certain corporate functions, th e Vascular Solutions integration program (initiated in 2017) and the 2016 and 2014 Footprint realignment plans. (3) The 2016 Footprint realignment plan involved the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. The program is substantially complete and the Company expects future restructuring expenses associated with the program, if any, to be immaterial. (4) Includes the Vascular Solutions integration program, the 2014 Footprint realignment plan and the EMEA restructuring program (initiated in 2017).
Summary Of Current Cost Estimates By Major Type Of Cost Table	These actions are expected to be substantially completed during 2022. The following table provides a summary of the Company’s estimates of restructuring and restructuring related charges by major type of expense associated with the 2019 Footprint realignment plan: Type of expense Total estimated amount expected to be incurred Termination benefits $19 million to $23 million Other exit costs (1) $1 million to $2 million Restructuring charges $20 million to $25 million Restructuring related charges (2) $36 million to $45 million Total restructuring and restructuring related charges $56 million to $70 million (1) Includes facility closure, employee relocation, equipment relocation and outplacement costs.

Inventories, net (Tables)

Inventories, net (Tables)	9 Months Ended
	Sep. 29, 2019
Inventory Disclosure [Abstract]
Inventories, net	Inventories as of September 29, 2019 and December 31, 2018 consisted of the following: September 29, 2019 December 31, 2018 (Dollars in thousands) Raw materials $ 121,080 $ 111,105 Work-in-process 72,211 62,334 Finished goods 279,303 254,339 Inventories, net $ 472,594 $ 427,778

Goodwill and other intangible_2

Goodwill and other intangible assets, net (Tables)	9 Months Ended
	Sep. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the nine months ended September 29, 2019: Americas EMEA Asia OEM Total (Dollars in thousands) December 31, 2018 $ 1,549,534 $ 480,615 $ 211,547 $ 4,883 $ 2,246,579 Goodwill related to acquisitions 441 189 1,211 — 1,841 Currency translation adjustment (4,055) (11,667) (1,368) — (17,090) September 29, 2019 $ 1,545,920 $ 469,137 $ 211,390 $ 4,883 $ 2,231,330
Schedule of Finite-Lived Intangible Assets	The Company's gross carrying amount of, and accumulated amortization relating to, intangible assets as of September 29, 2019 and December 31, 2018 were as follows: Gross Carrying Amount Accumulated Amortization September 29, 2019 December 31, 2018 September 29, 2019 December 31, 2018 (Dollars in thousands) Customer relationships $ 1,011,462 $ 1,030,194 $ (354,140) $ (322,972) In-process research and development 27,432 28,457 — — Intellectual property 1,342,956 1,363,516 (379,332) (322,539) Distribution rights 23,274 23,465 (18,492) (17,860) Trade names 560,613 565,070 (46,878) (36,379) Non-compete agreements 22,215 23,004 (13,437) (8,904) $ 2,987,952 $ 3,033,706 $ (812,279) $ (708,654)

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 29, 2019
Leases [Abstract]
Schedule of Lessee, Operating Lease, Liability, Maturity	Maturities of lease liabilities September 29, 2019 (Dollars in thousands) 2019 $ 6,254 2020 25,527 2021 23,183 2022 21,423 2023 17,511 2024 and thereafter 54,172 Total lease payments 148,070 Less: interest (23,544) Present value of lease liabilities $ 124,526
Supplemental Information, Lessee, Operating Lease	Supplemental information as of and for the nine months ended September 29, 2019 (dollars in thousands) Total lease liabilities (1) $ 124,526 Cash paid for amounts included in the measurement of lease liabilities within operating cash flows $ 19,520 Right of use assets obtained in exchange for operating lease obligations $ 34,632 Weighted average remaining lease term 7.4 years Weighted average discount rate 4.4 % (1) The current portion of the operating lease liabilities of $20.4 million is included in Other current liabilities.
Future Minimum Lease Payments Under Noncancelable Operating Leases	As of December 31, 2018, minimum lease payments under noncancellable operating leases were expected to be as follows: December 31, 2018 (Dollars in thousands) 2019 $ 25,294 2020 23,216 2021 21,419 2022 19,460 2023 17,403 2024 and thereafter 41,368

Borrowings (Tables)

Borrowings (Tables)	9 Months Ended
	Sep. 29, 2019
Debt Disclosure [Abstract]
Components of Long-Term Debt	The Company's borrowings at September 29, 2019 and December 31, 2018 were as follows: September 29, 2019 December 31, 2018 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 3.55% at September 29, 2019, due 2024 $ 143,000 $ 293,000 Term loan facility, at a rate of 3.55% at September 29, 2019, due 2024 673,000 683,500 5.25% Senior Notes due 2024 250,000 250,000 4.875% Senior Notes due 2026 400,000 400,000 4.625% Senior Notes due 2027 500,000 500,000 Securitization program, at a rate of 2.78% at September 29, 2019 50,000 50,000 2,016,000 2,176,500 Less: Unamortized debt issuance costs (16,932) (17,675) 1,999,068 2,158,825 Current borrowings (50,000) (86,625) Long-term borrowings $ 1,949,068 $ 2,072,200

Financial instruments (Tables)

Financial instruments (Tables)	9 Months Ended
	Sep. 29, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments Designated as Hedging Instruments	The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of September 29, 2019 and December 31, 2018: September 29, 2019 December 31, 2018 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 998 $ 1,216 Non-designated foreign currency forward contracts 289 106 Cross-currency interest rate swap 26,754 14,728 Prepaid expenses and other current assets 28,041 16,050 Cross-currency interest rate swap 23,857 — Other assets 23,857 — Total asset derivatives $ 51,898 $ 16,050 Liability derivatives: Designated foreign currency forward contracts $ 795 $ 524 Non-designated foreign currency forward contracts 137 264 Other current liabilities 932 788 Cross-currency interest rate swap — 7,793 Other liabilities — 7,793 Total liability derivatives $ 932 $ 8,581

Fair value measurement (Tables)

Fair value measurement (Tables)	9 Months Ended
	Sep. 29, 2019
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of September 29, 2019 and December 31, 2018: Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 10,168 $ 10,168 $ — $ — Derivative assets 51,898 — 51,898 — Derivative liabilities 932 — 932 — Contingent consideration liabilities 206,880 — — 206,880 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 8,671 $ 8,671 $ — $ — Derivative assets 16,050 — 16,050 — Derivative liabilities 8,581 — 8,581 — Contingent consideration liabilities 304,248 — — 304,248
Schedule of Valuation Techniques	The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration. Contingent Consideration Liability Valuation Technique Unobservable Input Range Milestone-based payments Discounted cash flow Discount rate 3.1% - 3.7% Projected year of payment 2020 - 2023 Revenue-based payments Monte Carlo simulation Revenue volatility 18.6% - 23.9% Risk free rate Cost of debt structure Projected year of payment 2020 - 2022 Discounted cash flow Discount rate 10.0% Projected year of payment 2019 - 2029
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes in the Company's contingent consideration liabilities during the nine months ended September 29, 2019: Contingent consideration 2019 (Dollars in thousands) Balance - December 31, 2018 $ 304,248 Payments (1) (138,098) Revaluations 40,894 Translation adjustment (164) Balance - September 29, 2019 $ 206,880

Shareholders' equity (Tables)

Shareholders' equity (Tables)	9 Months Ended
	Sep. 29, 2019
Equity [Abstract]
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Shares in thousands) Basic 46,248 45,851 46,156 45,587 Dilutive effect of share-based awards 928 919 895 1,007 Dilutive effect of convertible warrants — 45 — 191 Diluted 47,176 46,815 47,051 46,785
Change in Accumulated Other Comprehensive Income (Loss)	The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the nine months ended September 29, 2019 and September 30, 2018: Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2018 $ 807 $ (131,380) $ (210,512) $ (341,085) Other comprehensive income (loss) before reclassifications 646 215 (27,562) (26,701) Amounts reclassified from accumulated other comprehensive income (748) 4,033 — 3,285 Net current-period other comprehensive (loss) income (102) 4,248 (27,562) (23,416) Balance as of September 29, 2019 $ 705 $ (127,132) $ (238,074) $ (364,501) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2017 $ 340 $ (138,808) $ (126,623) $ (265,091) Other comprehensive income (loss) before reclassifications 2,816 127 (30,130) (27,187) Amounts reclassified from accumulated other comprehensive loss (873) 3,984 — 3,111 Net current-period other comprehensive income (loss) 1,943 4,111 (30,130) (24,076) Balance as of September 30, 2018 $ 2,283 $ (134,697) $ (156,753) $ (289,167)
Reclassification of Gain/Losses into Income/Expense, Net of Tax	The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and nine months ended September 29, 2019 and September 30, 2018: Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (523) $ (87) $ (888) $ (1,038) Total before tax (523) (87) (888) (1,038) Taxes (benefit) 46 25 140 165 Net of tax $ (477) $ (62) $ (748) $ (873) Losses (gains) on cross-currency swaps (net investment hedge): Interest expense $ (5,021) $ — $ (13,820) $ — Total before tax (5,021) — (13,820) — Tax expense $ 1,164 — 3,204 — Net of tax (3,857) $ — $ (10,616) $ — Amortization of pension and other postretirement benefit items (1) : Actuarial losses $ 1,716 $ 1,640 $ 5,194 $ 5,120 Prior-service costs 21 24 65 71 Total before tax 1,737 1,664 5,259 5,191 Tax benefit (405) (388) (1,226) (1,207) Net of tax $ 1,332 $ 1,276 $ 4,033 $ 3,984 Total reclassifications, net of tax $ (3,002) $ 1,214 $ (7,331) $ 3,111 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans.

Taxes on income from continui_2

Taxes on income from continuing operations (Tables)	9 Months Ended
	Sep. 29, 2019
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Effective income tax rate (132.3)% (2.3)% (48.4)% 11.8%

Segment information (Tables)

Segment information (Tables)	9 Months Ended
	Sep. 29, 2019
Segment Reporting [Abstract]
Segment Results	The following tables present the Company’s segment results for the three and nine months ended September 29, 2019 and September 30, 2018: Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Dollars in thousands) Americas $ 374,493 $ 338,749 $ 1,092,321 $ 993,455 EMEA 140,518 139,541 442,110 452,826 Asia 77,864 76,544 213,869 207,201 OEM 55,444 54,838 166,110 153,286 Net revenues $ 648,319 $ 609,672 $ 1,914,410 $ 1,806,768 Three Months Ended Nine Months Ended September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 (Dollars in thousands) Americas $ 81,405 $ 68,559 $ 229,513 $ 174,764 EMEA 21,820 21,916 69,670 80,221 Asia 21,460 20,834 50,699 54,948 OEM 16,008 15,049 43,213 37,617 Total segment operating profit (1) 140,693 126,358 393,095 347,550 Unallocated expenses (2) (23,072) (44,253) (92,773) (145,112) Income from continuing operations before interest and taxes $ 117,621 $ 82,105 $ 300,322 $ 202,438 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.

Condensed consolidating guara_2

Condensed consolidating guarantor financial information (Tables)	9 Months Ended
	Sep. 29, 2019
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended September 29, 2019 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 449,753 $ 338,889 $ (140,323) $ 648,319 Cost of goods sold — 290,466 112,090 (129,917) 272,639 Gross profit — 159,287 226,799 (10,406) 375,680 Selling, general and administrative expenses 14,919 140,053 75,421 (497) 229,896 Research and development expenses 334 20,321 7,329 — 27,984 Restructuring and impairment charges — 661 607 — 1,268 Gain on sale of assets — — (1,089) — (1,089) (Loss) income from continuing operations before interest and taxes (15,253) (1,748) 144,531 (9,909) 117,621 Interest, net 25,367 (20,911) 14,619 — 19,075 (Loss) income from continuing operations before taxes (40,620) 19,163 129,912 (9,909) 98,546 (Benefit) taxes on (loss) income from continuing operations (13,374) 4,393 (119,578) (1,824) (130,383) Equity in net income of consolidated subsidiaries 256,175 229,630 — (485,805) — Income from continuing operations 228,929 244,400 249,490 (493,890) 228,929 Operating loss from discontinued operations (9) — — — (9) Tax benefit on loss from discontinued operations (9) — — — (9) Income from discontinued operations — — — — — Net income 228,929 244,400 249,490 (493,890) 228,929 Other comprehensive income (38,594) (58,995) (62,882) 121,877 (38,594) Comprehensive income $ 190,335 $ 185,405 $ 186,608 $ (372,013) $ 190,335 Three Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed Consolidated (Dollars in thousands) Net revenues $ — $ 398,961 $ 322,010 $ (111,299) $ 609,672 Cost of goods sold — 232,209 146,301 (111,411) 267,099 Gross profit — 166,752 175,709 112 342,573 Selling, general and administrative expenses 11,347 130,769 72,800 (22) 214,894 Research and development expenses 378 19,482 6,505 — 26,365 Restructuring and impairment charges — 17,128 2,081 — 19,209 (Loss) income from continuing operations before interest and taxes (11,725) (627) 94,323 134 82,105 Interest, net 25,191 (15,391) 17,051 — 26,851 (Loss) income from continuing operations before taxes (36,916) 14,764 77,272 134 55,254 (Benefit) taxes on (loss) income from continuing operations (13,449) 1,765 10,385 13 (1,286) Equity in net income of consolidated subsidiaries 80,007 56,818 372 (137,197) — Income from continuing operations 56,540 69,817 67,259 (137,076) 56,540 Operating loss from discontinued operations (83) — — — (83) Tax benefit on loss from discontinued operations (67) — — — (67) Income from discontinued operations (16) — — — (16) Net income 56,524 69,817 67,259 (137,076) 56,524 Other comprehensive loss 17,253 14,107 16,947 (31,054) 17,253 Comprehensive income $ 73,777 $ 83,924 $ 84,206 $ (168,130) $ 73,777 Nine Months Ended September 29, 2019 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 1,304,385 $ 987,478 $ (377,453) $ 1,914,410 Cost of goods sold — 769,639 411,370 (359,945) 821,064 Gross profit — 534,746 576,108 (17,508) 1,093,346 Selling, general and administrative expenses 45,398 413,380 235,402 (405) 693,775 Research and development expenses 1,414 60,773 20,542 — 82,729 Restructuring and impairment charges — 6,742 13,606 — 20,348 Gain on sale of assets — — (3,828) — (3,828) (Loss) income from continuing operations before interest and taxes (46,812) 53,851 310,386 (17,103) 300,322 Interest, net 58,782 (42,756) 45,688 — 61,714 (Loss) income from continuing operations before taxes (105,594) 96,607 264,698 (17,103) 238,608 (Benefit) taxes on (loss) income from continuing operations (41,765) 31,643 (102,388) (3,057) (115,567) Equity in net income of consolidated subsidiaries 418,004 330,627 — (748,631) — Income from continuing operations 354,175 395,591 367,086 (762,677) 354,175 Operating loss from discontinued operations (1,291) — — — (1,291) Tax benefit on loss from discontinued operations (317) — — — (317) Loss from discontinued operations (974) — — — (974) Net income 353,201 395,591 367,086 (762,677) 353,201 Other comprehensive income (23,416) (43,389) (48,419) 91,808 (23,416) Comprehensive income $ 329,785 $ 352,202 $ 318,667 $ (670,869) $ 329,785 Nine Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 1,169,684 $ 968,298 $ (331,214) $ 1,806,768 Cost of goods sold — 681,300 431,841 (324,994) 788,147 Gross profit — 488,384 536,457 (6,220) 1,018,621 Selling, general and administrative expenses 32,958 400,987 226,555 (352) 660,148 Research and development expenses 1,094 57,668 19,648 — 78,410 Restructuring and impairment charges — 20,581 57,044 — 77,625 (Loss) income from continuing operations before interest and taxes (34,052) 9,148 233,210 (5,868) 202,438 Interest, net 72,120 (41,406) 48,273 — 78,987 (Loss) income from continuing operations before taxes (106,172) 50,554 184,937 (5,868) 123,451 (Benefit) taxes on (loss) income from continuing operations (39,859) 23,233 32,248 (1,090) 14,532 Equity in net income of consolidated subsidiaries 176,511 135,425 1,007 (312,943) — Income from continuing operations 110,198 162,746 153,696 (317,721) 108,919 Operating (loss) income from discontinued operations (33) — 1,279 — 1,246 Tax benefit on income (loss) from discontinued operations (47) — — — (47) Income from discontinued operations 14 — 1,279 — 1,293 Net income 110,212 162,746 154,975 (317,721) 110,212 Other comprehensive loss (24,076) (30,691) (26,551) 57,242 (24,076) Comprehensive income $ 86,136 $ 132,055 $ 128,424 $ (260,479) $ 86,136
Condensed Consolidating Balance Sheets	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS September 29, 2019 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 34,196 $ 518 $ 222,830 $ — $ 257,544 Accounts receivable, net 3,228 69,322 318,375 5,738 396,663 Accounts receivable from consolidated subsidiaries 33,739 469,533 511,784 (1,015,056) — Inventories, net — 296,136 224,660 (48,202) 472,594 Prepaid expenses and other current assets 40,513 10,387 26,518 4,113 81,531 Prepaid taxes 19,518 — 9,760 — 29,278 Total current assets 131,194 845,896 1,313,927 (1,053,407) 1,237,610 Property, plant and equipment, net 2,889 246,496 180,183 — 429,568 Operating lease assets 13,136 68,830 33,227 — 115,193 Goodwill — 1,255,976 975,354 — 2,231,330 Intangibles assets, net 75 1,214,148 961,450 — 2,175,673 Investments in affiliates 5,824,869 2,138,760 924,448 (8,888,077) — Deferred tax assets 6,850 — 5,298 (9,196) 2,952 Notes receivable and other amounts due from consolidated subsidiaries 1,959,149 3,407,412 287,571 (5,654,132) — Other assets 42,666 12,017 10,173 — 64,856 Total assets $ 7,980,828 $ 9,189,535 $ 4,691,631 $ (15,604,812) $ 6,257,182 LIABILITIES AND EQUITY Current liabilities Current borrowings $ — $ — $ 50,000 $ — $ 50,000 Accounts payable 3,004 61,106 36,520 — 100,630 Accounts payable to consolidated subsidiaries 284,386 428,967 301,703 (1,015,056) — Accrued expenses 6,287 33,398 51,884 — 91,569 Current portion of contingent consideration — 124,789 10,379 — 135,168 Payroll and benefit-related liabilities 19,772 35,171 44,888 — 99,831 Accrued interest 19,658 — 28 — 19,686 Income taxes payable — — 6,356 (3,057) 3,299 Other current liabilities 4,049 14,849 11,282 — 30,180 Total current liabilities 337,156 698,280 513,040 (1,018,113) 530,363 Long-term borrowings 1,949,068 — — — 1,949,068 Deferred tax liabilities — 345,670 132,471 (9,196) 468,945 Pension and postretirement benefit liabilities 30,594 25,887 15,535 — 72,016 Noncurrent liability for uncertain tax positions 1,162 7,382 2,540 — 11,084 Notes payable and other amounts due to consolidated subsidiaries 2,673,870 1,860,819 1,119,443 (5,654,132) — Noncurrent contingent consideration — 44,137 27,575 — 71,712 Noncurrent operating lease liabilities 10,616 68,167 25,353 — 104,136 Other liabilities 125,386 9,619 61,877 — 196,882 Total liabilities 5,127,852 3,059,961 1,897,834 (6,681,441) 3,404,206 Total shareholders' equity 2,852,976 6,129,574 2,793,797 (8,923,371) 2,852,976 Total liabilities and shareholders' equity $ 7,980,828 $ 9,189,535 $ 4,691,631 $ (15,604,812) $ 6,257,182 December 31, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 49,523 $ 1,701 $ 305,937 $ — $ 357,161 Accounts receivable, net 5,885 54,013 301,054 5,334 366,286 Accounts receivable from consolidated subsidiaries 32,036 1,122,107 366,033 (1,520,176) — Inventories, net — 266,073 192,659 (30,954) 427,778 Prepaid expenses and other current assets 30,458 9,673 28,237 4,113 72,481 Prepaid taxes 7,029 — 5,434 — 12,463 Total current assets 124,931 1,453,567 1,199,354 (1,541,683) 1,236,169 Property, plant and equipment, net 3,385 253,037 176,344 — 432,766 Goodwill — 1,254,848 991,731 — 2,246,579 Intangibles assets, net 90 1,277,462 1,047,500 — 2,325,052 Investments in affiliates 5,984,566 1,625,464 837,899 (8,447,929) — Deferred tax assets — — 4,822 (2,376) 2,446 Notes receivable and other amounts due from consolidated subsidiaries 2,337,737 3,347,815 13,242 (5,698,794) — Other assets 17,180 5,776 12,023 — 34,979 Total assets $ 8,467,889 $ 9,217,969 $ 4,282,915 $ (15,690,782) $ 6,277,991 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,625 $ — $ 50,000 $ — $ 86,625 Accounts payable 3,448 62,764 40,497 — 106,709 Accounts payable to consolidated subsidiaries 1,058,008 292,093 170,075 (1,520,176) — Accrued expenses 5,659 41,873 50,019 — 97,551 Current portion of contingent consideration — 106,514 30,363 — 136,877 Payroll and benefit-related liabilities 17,156 44,982 42,532 — 104,670 Accrued interest 5,995 — 36 — 6,031 Income taxes payable — — 5,943 — 5,943 Other current liabilities 843 34,916 2,291 — 38,050 Total current liabilities 1,127,734 583,142 391,756 (1,520,176) 582,456 Long-term borrowings 2,072,200 — — — 2,072,200 Deferred tax liabilities 87,671 257,522 265,404 (2,376) 608,221 Pension and postretirement benefit liabilities 49,290 27,454 16,170 — 92,914 Noncurrent liability for uncertain tax positions 801 7,212 2,705 — 10,718 Notes payable and other amounts due to consolidated subsidiaries 2,451,784 2,222,580 1,024,430 (5,698,794) — Noncurrent contingent consideration — 131,563 35,807 — 167,370 Other liabilities 138,431 8,204 57,499 204,134 Total liabilities 5,927,911 3,237,677 1,793,771 (7,221,346) 3,738,013 Total shareholders' equity 2,539,978 5,980,292 2,489,144 (8,469,436) 2,539,978 Total liabilities and shareholders' equity $ 8,467,889 $ 9,217,969 $ 4,282,915 $ (15,690,782) $ 6,277,991
Condensed Consolidating Statements of Cash Flows	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Nine Months Ended September 29, 2019 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (72,369) $ 342,912 $ 272,115 $ (253,491) $ 289,167 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (460) (57,131) (26,206) — (83,797) Proceeds from sale of assets and investments 2,362 2,046 1,089 (2,362) 3,135 Payments for businesses and intangibles acquired, net of cash acquired — (1,025) (240) — (1,265) Net interest proceeds on swaps designated as net investment hedges 8,330 — — — 8,330 Investments in affiliates — (146) — 146 — Net cash provided by (used in) investing activities from continuing operations 10,232 (56,256) (25,357) (2,216) (73,597) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 25,000 — — — 25,000 Reduction in borrowings (185,500) — — — (185,500) Debt extinguishment, issuance and amendment fees (4,964) — — — (4,964) Net proceeds from share based compensation plans and the related tax impacts 14,014 — — — 14,014 Payments for contingent consideration — (15,122) (96,884) — (112,006) Proceeds from issuance of shares — — 146 (146) — Dividends paid (47,071) — — — (47,071) Intercompany transactions 242,049 (272,773) 28,362 2,362 — Intercompany dividends paid — — (253,491) 253,491 — Net cash provided by (used in) financing activities from continuing operations 43,528 (287,895) (321,867) 255,707 (310,527) Cash flows from discontinued operations: Net cash provided by (used in) operating activities 3,282 — (631) — 2,651 Net cash provided by (used in) discontinued operations 3,282 — (631) — 2,651 Effect of exchange rate changes on cash and cash equivalents — — (7,311) — (7,311) Net (decrease) increase in cash and cash equivalents (15,327) (1,239) (83,051) — (99,617) Cash and cash equivalents at the beginning of the period 49,523 1,757 305,881 — 357,161 Cash and cash equivalents at the end of the period $ 34,196 $ 518 $ 222,830 $ — $ 257,544 Nine Months Ended September 30, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (202,209) $ 321,389 $ 329,390 $ (145,626) $ 302,944 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (1,524) (23,686) (30,541) — (55,751) Proceeds from sale of assets 28,239 — — (28,239) — Payments for businesses and intangibles acquired, net of cash acquired (100) — (22,450) — (22,550) Net cash provided by (used in) investing activities from continuing operations 26,615 (23,686) (52,991) (28,239) (78,301) Cash flows from financing activities of continuing operations: Reduction in borrowings (98,500) — — — (98,500) Debt extinguishment, issuance and amendment fees (188) — — — (188) Net proceeds from share based compensation plans and the related tax impacts 18,666 — — — 18,666 Payments for contingent consideration — (10,748) (62,404) — (73,152) Dividends paid (46,526) — — — (46,526) Intercompany transactions 312,806 (294,600) (46,445) 28,239 — Intercompany dividends paid — — (145,626) 145,626 — Net cash provided by (used in) financing activities from continuing operations 186,258 (305,348) (254,475) 173,865 (199,700) Cash flows from discontinued operations: Net cash used in operating activities (701) — — — (701) Net cash used in discontinued operations (701) — — — (701) Effect of exchange rate changes on cash and cash equivalents — — (1,524) — (1,524) Net increase (decrease) in cash and cash equivalents 9,963 (7,645) 20,400 — 22,718 Cash and cash equivalents at the beginning of the period 37,803 8,933 286,822 — 333,558 Cash and cash equivalents at the end of the period $ 47,766 $ 1,288 $ 307,222 $ — $ 356,276

Recently issued accounting st_3

Recently issued accounting standards (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease assets	$ 115,193
Operating lease liabilities	$ 124,526
ASU 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease assets		$ 105,300
Operating lease liabilities		$ 106,600

Net revenues (Details)

Net revenues (Details) - Sales Revenue, Net - Customer Concentration Risk	9 Months Ended
	Sep. 29, 2019
Hospitals And Healthcare Providers
Concentration Risk [Line Items]
Percentage of total revenue	88.00%
Other Medical Device Manufacturers
Concentration Risk [Line Items]
Percentage of total revenue	10.00%
Home Care Providers
Concentration Risk [Line Items]
Percentage of total revenue	2.00%

Net revenues Other revenues (De

Net revenues Other revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Revenue, Major Customer [Line Items]
Net revenues	$ 648,319	$ 609,672	$ 1,914,410	$ 1,806,768
Vascular access
Revenue, Major Customer [Line Items]
Net revenues	148,681	142,079	446,225	426,256
Anesthesia
Revenue, Major Customer [Line Items]
Net revenues	87,123	87,531	253,098	261,764
Interventional
Revenue, Major Customer [Line Items]
Net revenues	106,883	99,975	314,852	288,306
Surgical
Revenue, Major Customer [Line Items]
Net revenues	92,621	89,908	274,911	266,046
Interventional urology
Revenue, Major Customer [Line Items]
Net revenues	73,629	48,995	201,312	138,969
OEM
Revenue, Major Customer [Line Items]
Net revenues	55,444	54,838	166,110	153,286
Other
Revenue, Major Customer [Line Items]
Net revenues	$ 83,938	$ 86,346	$ 257,902	$ 272,141

Divestitures - Narrative (Detai

Divestitures - Narrative (Details) - USD ($) $ in Thousands	Feb. 04, 2019	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain (Loss) on Disposition of Assets		$ 1,089	$ 0	$ 3,828	$ 0
Notes Receivable
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Receivable with imputed interest, face amount	$ 10,500
Financing receivables, payments to be received in next twelve months	2,100
Financing receivables, payments to be received in year two	2,100
Financing receivables, payments to be received in year three	2,100
Financing receivables, payments to be received in year four	2,100
Financing receivables, payments to be received in year five	2,100
Notes receivable, fair value disclosure	7,600
Financing receivable, net		8,300		8,300
Notes Receivable | Accounts Receivable
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Financing receivable, net		2,100		2,100
Notes Receivable | Other assets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Financing receivable, net		6,200		6,200
Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group, including discontinued operation, consideration	12,600
Gain (Loss) on Disposition of Assets	$ 2,700
Disposal group, including discontinued operation, assets		$ 9,700		$ 9,700

Restructuring and impairment _3

Restructuring and impairment charges (credits) - Charges Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 1,268	$ 1,964	$ 13,437	$ 58,515
Asset impairment charges		17,245	6,911	19,110
Restructuring and impairment charges	1,268	19,209	20,348	77,625
Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	906	1,587	11,772	57,160
Asset impairment charges		0	0	0
Restructuring and impairment charges		1,587	11,772	57,160
Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	362	377	1,665	1,355
Asset impairment charges		17,245	6,911	19,110
Restructuring and impairment charges		17,622	8,576	20,465
2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	622		13,168
2019 Footprint realignment plan | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	584		13,100
2019 Footprint realignment plan | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	38		68
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	389	1,264	(741)	53,738
2018 Footprint realignment plan | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	315	1,119	(1,523)	53,463
2018 Footprint realignment plan | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	74	145	782	275
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	257	700	1,010	1,981
Other restructuring programs | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	7	468	195	1,318
Other restructuring programs | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 250	$ 232	$ 815	663
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges				2,796
2016 Footprint realignment plan | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges				2,379
2016 Footprint realignment plan | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$ 417

Restructuring and impairment _4

Restructuring and impairment charges (credits) - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Feb. 28, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cash payment		$ 1.8	$ 2.8
2019 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cash payment	$ 1.9		3.6
Restructuring reserve	11.8		11.8
2019 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					$ 56
2019 Footprint realignment plan | Minimum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					36
2019 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					70
2019 Footprint realignment plan | Maximum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					$ 45
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cash payment	0.8		2.1
Restructuring reserve	44		44
Aggregate restructuring charges incurred	54.3		54.3
Restructuring expenses			6.2
2018 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	102		102
2018 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	133		133
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	3.7		3.7
Aggregate restructuring charges incurred	12.8		12.8
Restructuring expenses			31.2
2014 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	0.8	$ 0.8	2.1	$ 1.8
2014 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	47		47
2014 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 52		$ 52

Restructuring and impairment _5

Restructuring and impairment charges (credits) - Cost Estimates By Major Type of Expense (Details) - 2019 Footprint realignment plan $ in Millions	Feb. 28, 2019USD ($)
Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 56
Minimum | Termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	19
Minimum | Other exit costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	1
Minimum | Special Termination Benefit And Other Restructuring
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	20
Minimum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	36
Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	70
Maximum | Termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	23
Maximum | Other exit costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2
Maximum | Special Termination Benefit And Other Restructuring
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	25
Maximum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 45

Inventories, net (Detail)

Inventories, net (Detail) - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 121,080	$ 111,105
Work-in-process	72,211	62,334
Finished goods	279,303	254,339
Inventories, net	$ 472,594	$ 427,778

Goodwill and other intangible_3

Goodwill and other intangible assets, net - Changes in carrying amount of goodwill, by reporting segment (Details) $ in Thousands	9 Months Ended
	Sep. 29, 2019USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 2,246,579
Goodwill related to acquisitions	1,841
Currency translation adjustment	(17,090)
Goodwill, ending balance	2,231,330
Americas
Goodwill [Roll Forward]
Goodwill, beginning balance	1,549,534
Goodwill related to acquisitions	441
Currency translation adjustment	(4,055)
Goodwill, ending balance	1,545,920
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	480,615
Goodwill related to acquisitions	189
Currency translation adjustment	(11,667)
Goodwill, ending balance	469,137
Asia
Goodwill [Roll Forward]
Goodwill, beginning balance	211,547
Goodwill related to acquisitions	1,211
Currency translation adjustment	(1,368)
Goodwill, ending balance	211,390
OEM
Goodwill [Roll Forward]
Goodwill, beginning balance	4,883
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	$ 4,883

Goodwill and other intangible_4

Goodwill and other intangible assets, net - Components of intangible assets (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,987,952	$ 3,033,706
Accumulated Amortization	(812,279)	(708,654)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
In-process research and development	27,432	28,457
Accumulated Amortization	0	0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,011,462	1,030,194
Accumulated Amortization	(354,140)	(322,972)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,342,956	1,363,516
Accumulated Amortization	(379,332)	(322,539)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	23,274	23,465
Accumulated Amortization	(18,492)	(17,860)
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	560,613	565,070
Accumulated Amortization	(46,878)	(36,379)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	22,215	23,004
Accumulated Amortization	$ (13,437)	$ (8,904)

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 29, 2019	Sep. 29, 2019
Lessee, Lease, Description [Line Items]
Lease, cost	$ 6.8	$ 19.5
Minimum
Lessee, Lease, Description [Line Items]
Lessee, operating lease, option to terminate or extend		1 year

Leases - Maturities of lease li

Leases - Maturities of lease liabilities (Details) $ in Thousands	Sep. 29, 2019USD ($)
Leases [Abstract]
2019	$ 6,254
2020	25,527
2021	23,183
2022	21,423
2023	17,511
2024 and thereafter	54,172
Total lease payments	148,070
Less: interest	(23,544)
Present value of lease liabilities	$ 124,526

Leases - Supplemental balance s

Leases - Supplemental balance sheet information (Details) $ in Thousands	9 Months Ended
	Sep. 29, 2019USD ($)
Leases [Abstract]
Operating lease liabilities	$ 124,526
Cash paid for amounts included in the measurement of lease liabilities within operating cash flows	19,520
Right of use assets obtained in exchange for operating lease obligations	$ 34,632
Weighted average remaining lease term	7 years 4 months 24 days
Weighted average discount rate	4.40%
Other current liabilities
Lessee, Lease, Description [Line Items]
Current operating lease liabilities	$ 20,400

Leases - Future minimum lease p

Leases - Future minimum lease payments under noncancelable operating leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 25,294
2020	23,216
2021	21,419
2022	19,460
2023	17,403
2024 and thereafter	$ 41,368

Borrowings - Components of long

Borrowings - Components of long-term debt (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 29, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,016,000	$ 2,176,500
Less: Unamortized debt issuance costs	(16,932)	(17,675)
Total long-term debt	1,999,068	2,158,825
Current borrowings	(50,000)	(86,625)
Long-term borrowings	1,949,068	2,072,200
Revolving Credit Facility
Debt Instrument [Line Items]
Long-term line of credit	$ 143,000	293,000
Line of credit facility interest rate	3.55%
Term Loan
Debt Instrument [Line Items]
Long-term line of credit	$ 673,000	683,500
Line of credit facility interest rate	3.55%
Senior Notes | 5.25% Senior Notes due 2024
Debt Instrument [Line Items]
Senior notes	$ 250,000	250,000
Debt instrument, stated interest rate	5.25%
Senior Notes | 4.875% Senior Notes due 2026
Debt Instrument [Line Items]
Senior notes	$ 400,000	400,000
Debt instrument, stated interest rate	4.875%
Senior Notes | 4.625% Senior Notes due 2027
Debt Instrument [Line Items]
Senior notes	$ 500,000	500,000
Debt instrument, stated interest rate	4.625%
Securitization program
Debt Instrument [Line Items]
Securitization program, at a rate of 2.78% at September 29, 2019	$ 50,000	$ 50,000
Debt instrument, stated interest rate	2.78%

Borrowings - Additional Informa

Borrowings - Additional Information (Details) - Second Amended and Restated Credit Agreement	Apr. 05, 2019USD ($)
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	2.00%
Maximum leverage ratio	4.50
Minimum interest coverage ratio	3.50
Capitalized transactions fees, including underwrites' discounts and commissions incurred	$ 3,900,000
London Interbank Offered Rate (LIBOR) | Minimum
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.25%
London Interbank Offered Rate (LIBOR) | Maximum
Line of Credit Facility [Line Items]
Basis spread on variable rate	2.00%
Federal Funds Effective Swap Rate
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
Adjusted LIBOR
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Adjusted LIBOR | Minimum
Line of Credit Facility [Line Items]
Basis spread on variable rate	0.125%
Adjusted LIBOR | Maximum
Line of Credit Facility [Line Items]
Basis spread on variable rate	1.00%
Revolving Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Term Loan
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 700,000,000

Financial instruments - Additio

Financial instruments - Additional Information (Details) € in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 29, 2019USD ($)	Sep. 30, 2018USD ($)	Mar. 04, 2019EUR (€)Financial_Institution_Counterparty	Mar. 04, 2019USD ($)Financial_Institution_Counterparty	Dec. 31, 2018USD ($)	Oct. 04, 2018EUR (€)Financial_Institution_Counterparty	Oct. 04, 2018USD ($)Financial_Institution_Counterparty
Derivatives Fair Value [Line Items]
Foreign currency translation, continuing operations, adjustments, net of tax	$ (39,894,000)	$ 14,387,000	$ (27,562,000)	$ (30,130,000)
Net revenues	648,319,000	609,672,000	1,914,410,000	1,806,768,000
Allowance for doubtful accounts receivable	9,100,000		9,100,000				$ 9,300,000
Allowance for doubtful accounts receivable, current	5,300,000		5,300,000				4,400,000
Cash flow hedging
Derivatives Fair Value [Line Items]
Ineffectiveness related to derivatives	0	0	0	$ 0
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	115,600,000		115,600,000				115,300,000
Foreign exchange contract | Not Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Loss related to currency forward contracts	1,900,000		3,500,000
Gain related to currency forward contracts		$ 1,000,000	300,000
Total notional amount for all open foreign currency forward contracts	170,100,000		170,100,000				$ 125,900,000
Cross-currency interest rate swap | Cash flow hedging
Derivatives Fair Value [Line Items]
Foreign currency translation, continuing operations, adjustments, net of tax	$ 23,500,000		$ 29,400,000
Cross-currency interest rate swap | Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts					€ 219.2	$ 250,000,000		€ 433.9	$ 500,000,000
Derivative, number of instruments held | Financial_Institution_Counterparty					5	5		6	6
Derivative, fixed interest rate					4.875%	4.875%		4.625%	4.625%
Derivative, annual interest rate					2.4595%	2.4595%		1.942%	1.942%

Financial instruments - Fair va

Financial instruments - Fair values of derivative instruments designated as hedging instruments (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 31, 2018
Cash flow hedging
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 51,898	$ 16,050
Total liability derivatives	932	8,581
Cash flow hedging | Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	23,857	0
Foreign exchange contract | Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	0	7,793
Foreign exchange contract | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	28,041	16,050
Foreign exchange contract | Cash flow hedging | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	932	788
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	998	1,216
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	795	524
Foreign exchange contract | Not Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	289	106
Foreign exchange contract | Not Designated as Hedging Instrument | Cash flow hedging | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	137	264
Cross-currency interest rate swap | Not Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	26,754	14,728
Cross-currency interest rate swap | Not Designated as Hedging Instrument | Cash flow hedging | Other assets
Derivatives Fair Value [Line Items]
Total asset derivatives	23,857	0
Cross-currency interest rate swap | Not Designated as Hedging Instrument | Cash flow hedging | Other liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 0	$ 7,793

Financial instruments - Aggrega

Financial instruments - Aggregate accounts receivable, net of allowance for doubtful accounts (Details) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Allowance for doubtful accounts receivable	$ 9.1	$ 9.3
Allowance for doubtful accounts receivable, current	$ 5.3	$ 4.4

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 10,168	$ 8,671
Derivative assets	51,898	16,050
Derivative liabilities	932	8,581
Contingent consideration liabilities	206,880	304,248
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	10,168	8,671
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	51,898	16,050
Derivative liabilities	932	8,581
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 206,880	$ 304,248

Fair value measurement - Narrat

Fair value measurement - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)
NeoTract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Milestone payment	$ 106.8
Essential Medical, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Milestone payment	$ 30

Fair value measurement - Valuat

Fair value measurement - Valuation technique and inputs used in determining the fair value of contingent consideration (Details)	Sep. 29, 2019
Milestone-based payments | Minimum | Discounted cash flow | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.031
Milestone-based payments | Maximum | Discounted cash flow | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.037
Revenue-based payments | Discounted cash flow | Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.100
Revenue-based payments | Minimum | Monte Carlo simulation | Revenue volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.186
Revenue-based payments | Maximum | Monte Carlo simulation | Revenue volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business combination, contingent consideration, liability, measurement input	0.239

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in financial liabilities measured on recurring basis (Details) $ in Thousands	9 Months Ended
	Sep. 29, 2019USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 304,248
Payments	(138,098)
Revaluations	40,894
Translation adjustment	(164)
Ending balance	$ 206,880

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Equity Option
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	0.1	0.7	0.1	0.7

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Equity [Abstract]
Basic (in shares)	46,248	45,851	46,156	45,587
Dilutive effect of share-based awards (in shares)	928	919	895	1,007
Dilutive effect of convertible notes and warrants (in shares)	0	45	0	191
Diluted (in shares)	47,176	46,815	47,051	46,785

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income, net of tax (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$ 2,664,844	$ 2,433,981	$ 2,539,978	$ 2,430,531
Amounts reclassified from accumulated other comprehensive income	(3,002)	1,214	(7,331)	3,111
Ending Balance	2,852,976	2,507,065	2,852,976	2,507,065
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			807	340
Other comprehensive income (loss) before reclassifications			646	2,816
Amounts reclassified from accumulated other comprehensive income			(748)	(873)
Net current-period other comprehensive (loss) income			(102)	1,943
Ending Balance	705	2,283	705	2,283
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(131,380)	(138,808)
Other comprehensive income (loss) before reclassifications			215	127
Amounts reclassified from accumulated other comprehensive income	1,332	1,276	4,033	3,984
Net current-period other comprehensive (loss) income			4,248	4,111
Ending Balance	(127,132)	(134,697)	(127,132)	(134,697)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(210,512)	(126,623)
Other comprehensive income (loss) before reclassifications			(27,562)	(30,130)
Amounts reclassified from accumulated other comprehensive income			0	0
Net current-period other comprehensive (loss) income			(27,562)	(30,130)
Ending Balance	(238,074)	(156,753)	(238,074)	(156,753)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(325,907)	(306,420)	(341,085)	(265,091)
Other comprehensive income (loss) before reclassifications			(26,701)	(27,187)
Amounts reclassified from accumulated other comprehensive income			3,285	3,111
Net current-period other comprehensive (loss) income			(23,416)	(24,076)
Ending Balance	$ (364,501)	$ (289,167)	$ (364,501)	$ (289,167)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income into income expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ 272,639	$ 267,099	$ 821,064	$ 788,147
Total before tax	(98,546)	(55,254)	(238,608)	(123,451)
Taxes on income from continuing operations	130,383	1,286	115,567	(14,532)
Net of tax	(228,929)	(56,540)	(354,175)	(108,919)
Interest expense	19,545	27,171	62,995	79,763
Total reclassifications, net of tax	(3,002)	1,214	(7,331)	3,111
Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total reclassifications, net of tax			(748)	(873)
Actuarial losses
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,716	1,640	5,194	5,120
Prior-service costs
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	21	24	65	71
Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,737	1,664	5,259	5,191
Tax benefit	(405)	(388)	(1,226)	(1,207)
Total reclassifications, net of tax	1,332	1,276	4,033	3,984
Reclassification out of Accumulated Other Comprehensive Income | Foreign exchange contract | Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	(523)	(87)	(888)	(1,038)
Total before tax	(523)	(87)	(888)	(1,038)
Taxes on income from continuing operations	(46)	(25)	(140)	(165)
Net of tax	(477)	(62)	(748)	(873)
Reclassification out of Accumulated Other Comprehensive Income | Cross-currency interest rate swap | Net Investment Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	5,021	0	13,820	0
Taxes on income from continuing operations	1,164	0	3,204	0
Net of tax	(3,857)	0	(10,616)	0
Interest expense	$ (5,021)	$ 0	$ (13,820)	$ 0

Taxes on income from continui_3

Taxes on income from continuing operations (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Jul. 03, 2020
Income Tax Examination [Line Items]
Effective income tax rate	(132.30%)	(2.30%)	(48.40%)	11.80%
Forecast
Income Tax Examination [Line Items]
Increase (decrease) in deferred tax liability due to merger Of foreign subsidiaries					$ (129)

Commitments and contingent li_2

Commitments and contingent liabilities (Detail) $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)
Loss Contingencies [Line Items]
Estimated litigation liability	$ 0.2
Minimum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out	10 years
Maximum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out	15 years
Accrued Liabilities
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 0.9
Other Liability
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 6.3

Segment information (Details)

Segment information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 29, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 29, 2019USD ($)segment	Sep. 30, 2018USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			4
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 648,319	$ 609,672	$ 1,914,410	$ 1,806,768
Operating profit	117,621	82,105	300,322	202,438
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	140,693	126,358	393,095	347,550
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	(23,072)	(44,253)	(92,773)	(145,112)
Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	374,493	338,749	1,092,321	993,455
Americas | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	81,405	68,559	229,513	174,764
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	140,518	139,541	442,110	452,826
EMEA | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	21,820	21,916	69,670	80,221
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	77,864	76,544	213,869	207,201
Asia | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	21,460	20,834	50,699	54,948
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	55,444	54,838	166,110	153,286
OEM | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	$ 16,008	$ 15,049	$ 43,213	$ 37,617

Condensed consolidating guara_3

Condensed consolidating guarantor financial information - Additional Information (Detail) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Ownership percentage		100.00%
Senior Notes | 5.25% Senior Notes due 2024
Debt Instrument [Line Items]
Debt instrument, face amount		$ 250
Debt instrument, stated interest rate	5.25%
Senior Notes | 4.875% Senior Notes due 2026
Debt Instrument [Line Items]
Debt instrument, face amount		400
Debt instrument, stated interest rate	4.875%
Senior Notes | 4.625% Senior Notes due 2027
Debt Instrument [Line Items]
Debt instrument, face amount		$ 500
Debt instrument, stated interest rate	4.625%

Condensed consolidating guara_4

Condensed consolidating guarantor financial information - Income and Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 29, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jul. 01, 2018	Apr. 01, 2018	Sep. 29, 2019	Sep. 30, 2018
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 648,319			$ 609,672			$ 1,914,410	$ 1,806,768
Cost of goods sold	272,639			267,099			821,064	788,147
Gross profit	375,680			342,573			1,093,346	1,018,621
Selling, general and administrative expenses	229,896			214,894			693,775	660,148
Research and development expenses	27,984			26,365			82,729	78,410
Restructuring and impairment charges	1,268			19,209			20,348	77,625
Gain on sale of assets	(1,089)			0			(3,828)	0
Income from continuing operations before interest and taxes	117,621			82,105			300,322	202,438
Interest, net	19,075			26,851			61,714	78,987
Income from continuing operations before taxes	98,546			55,254			238,608	123,451
(Benefit) taxes on income from continuing operations	(130,383)			(1,286)			(115,567)	14,532
Equity in net income of consolidated subsidiaries	0			0			0	0
Income from continuing operations	228,929			56,540			354,175	108,919
Operating (loss) income from discontinued operations	(9)			(83)			(1,291)	1,246
Tax benefit on operating income (loss) from discontinued operations	(9)			(67)			(317)	(47)
Loss from discontinued operations	0			(16)			(974)	1,293
Net income	228,929	$ 83,375	$ 40,897	56,524	$ (2,496)	$ 56,184	353,201	110,212
Other comprehensive loss	(38,594)			17,253			(23,416)	(24,076)
Comprehensive income	190,335			73,777			329,785	86,136
Eliminations
Condensed Income Statements, Captions [Line Items]
Net revenues	(140,323)			(111,299)			(377,453)	(331,214)
Cost of goods sold	(129,917)			(111,411)			(359,945)	(324,994)
Gross profit	(10,406)			112			(17,508)	(6,220)
Selling, general and administrative expenses	(497)			(22)			(405)	(352)
Research and development expenses	0			0			0	0
Restructuring and impairment charges	0			0			0	0
Gain on sale of assets	0						0
Income from continuing operations before interest and taxes	(9,909)			134			(17,103)	(5,868)
Interest, net	0			0			0	0
Income from continuing operations before taxes	(9,909)			134			(17,103)	(5,868)
(Benefit) taxes on income from continuing operations	(1,824)			13			(3,057)	(1,090)
Equity in net income of consolidated subsidiaries	(485,805)			(137,197)			(748,631)	(312,943)
Income from continuing operations	(493,890)			(137,076)			(762,677)	(317,721)
Operating (loss) income from discontinued operations	0			0			0	0
Tax benefit on operating income (loss) from discontinued operations	0			0			0	0
Loss from discontinued operations	0			0			0	0
Net income	(493,890)			(137,076)			(762,677)	(317,721)
Other comprehensive loss	121,877			(31,054)			91,808	57,242
Comprehensive income	(372,013)			(168,130)			(670,869)	(260,479)
Parent Company
Condensed Income Statements, Captions [Line Items]
Net revenues	0			0			0	0
Cost of goods sold	0			0			0	0
Gross profit	0			0			0	0
Selling, general and administrative expenses	14,919			11,347			45,398	32,958
Research and development expenses	334			378			1,414	1,094
Restructuring and impairment charges	0			0			0	0
Gain on sale of assets	0						0
Income from continuing operations before interest and taxes	(15,253)			(11,725)			(46,812)	(34,052)
Interest, net	25,367			25,191			58,782	72,120
Income from continuing operations before taxes	(40,620)			(36,916)			(105,594)	(106,172)
(Benefit) taxes on income from continuing operations	(13,374)			(13,449)			(41,765)	(39,859)
Equity in net income of consolidated subsidiaries	256,175			80,007			418,004	176,511
Income from continuing operations	228,929			56,540			354,175	110,198
Operating (loss) income from discontinued operations	(9)			(83)			(1,291)	(33)
Tax benefit on operating income (loss) from discontinued operations	(9)			(67)			(317)	(47)
Loss from discontinued operations	0			(16)			(974)	14
Net income	228,929			56,524			353,201	110,212
Other comprehensive loss	(38,594)			17,253			(23,416)	(24,076)
Comprehensive income	190,335			73,777			329,785	86,136
Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	449,753			398,961			1,304,385	1,169,684
Cost of goods sold	290,466			232,209			769,639	681,300
Gross profit	159,287			166,752			534,746	488,384
Selling, general and administrative expenses	140,053			130,769			413,380	400,987
Research and development expenses	20,321			19,482			60,773	57,668
Restructuring and impairment charges	661			17,128			6,742	20,581
Gain on sale of assets	0						0
Income from continuing operations before interest and taxes	(1,748)			(627)			53,851	9,148
Interest, net	(20,911)			(15,391)			(42,756)	(41,406)
Income from continuing operations before taxes	19,163			14,764			96,607	50,554
(Benefit) taxes on income from continuing operations	4,393			1,765			31,643	23,233
Equity in net income of consolidated subsidiaries	229,630			56,818			330,627	135,425
Income from continuing operations	244,400			69,817			395,591	162,746
Operating (loss) income from discontinued operations	0			0			0	0
Tax benefit on operating income (loss) from discontinued operations	0			0			0	0
Loss from discontinued operations	0			0			0	0
Net income	244,400			69,817			395,591	162,746
Other comprehensive loss	(58,995)			14,107			(43,389)	(30,691)
Comprehensive income	185,405			83,924			352,202	132,055
Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	338,889			322,010			987,478	968,298
Cost of goods sold	112,090			146,301			411,370	431,841
Gross profit	226,799			175,709			576,108	536,457
Selling, general and administrative expenses	75,421			72,800			235,402	226,555
Research and development expenses	7,329			6,505			20,542	19,648
Restructuring and impairment charges	607			2,081			13,606	57,044
Gain on sale of assets	(1,089)						(3,828)
Income from continuing operations before interest and taxes	144,531			94,323			310,386	233,210
Interest, net	14,619			17,051			45,688	48,273
Income from continuing operations before taxes	129,912			77,272			264,698	184,937
(Benefit) taxes on income from continuing operations	(119,578)			10,385			(102,388)	32,248
Equity in net income of consolidated subsidiaries	0			372			0	1,007
Income from continuing operations	249,490			67,259			367,086	153,696
Operating (loss) income from discontinued operations	0			0			0	1,279
Tax benefit on operating income (loss) from discontinued operations	0			0			0	0
Loss from discontinued operations	0			0			0	1,279
Net income	249,490			67,259			367,086	154,975
Other comprehensive loss	(62,882)			16,947			(48,419)	(26,551)
Comprehensive income	$ 186,608			$ 84,206			$ 318,667	$ 128,424

Condensed consolidating guara_5

Condensed consolidating guarantor financial information - Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 29, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 257,544	$ 357,161
Accounts receivable, net	396,663	366,286
Accounts receivable from consolidated subsidiaries	0	0
Inventories, net	472,594	427,778
Prepaid expenses and other current assets	81,531	72,481
Prepaid taxes	29,278	12,463
Total current assets	1,237,610	1,236,169
Property, plant and equipment, net	429,568	432,766
Operating lease assets	115,193
Goodwill	2,231,330	2,246,579
Intangible assets, net	2,175,673	2,325,052
Investments in affiliates	0	0
Deferred tax assets	2,952	2,446
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	64,856	34,979
Total assets	6,257,182	6,277,991
Current liabilities
Current borrowings	50,000	86,625
Accounts payable	100,630	106,709
Accounts payable to consolidated subsidiaries	0	0
Accrued expenses	91,569	97,551
Current portion of contingent consideration	135,168	136,877
Payroll and benefit-related liabilities	99,831	104,670
Accrued interest	19,686	6,031
Income taxes payable	3,299	5,943
Other current liabilities	30,180	38,050
Total current liabilities	530,363	582,456
Long-term borrowings	1,949,068	2,072,200
Deferred tax liabilities	468,945	608,221
Pension and postretirement benefit liabilities	72,016	92,914
Noncurrent liability for uncertain tax positions	11,084	10,718
Notes payable and other amounts due to consolidated subsidiaries	0	0
Noncurrent contingent consideration	71,712	167,370
Noncurrent operating lease liabilities	104,136
Other liabilities	196,882	204,134
Total liabilities	3,404,206	3,738,013
Total shareholders' equity	2,852,976	2,539,978
Total liabilities and shareholders' equity	6,257,182	6,277,991
Eliminations
Current assets
Cash and cash equivalents	0	0
Accounts receivable, net	5,738	5,334
Accounts receivable from consolidated subsidiaries	(1,015,056)	(1,520,176)
Inventories, net	(48,202)	(30,954)
Prepaid expenses and other current assets	4,113	4,113
Prepaid taxes	0	0
Total current assets	(1,053,407)	(1,541,683)
Property, plant and equipment, net	0	0
Operating lease assets	0
Goodwill	0	0
Intangible assets, net	0	0
Investments in affiliates	(8,888,077)	(8,447,929)
Deferred tax assets	(9,196)	(2,376)
Notes receivable and other amounts due from consolidated subsidiaries	(5,654,132)	(5,698,794)
Other assets	0	0
Total assets	(15,604,812)	(15,690,782)
Current liabilities
Current borrowings	0	0
Accounts payable	0	0
Accounts payable to consolidated subsidiaries	(1,015,056)	(1,520,176)
Accrued expenses	0	0
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	0	0
Accrued interest	0	0
Income taxes payable	(3,057)	0
Other current liabilities	0	0
Total current liabilities	(1,018,113)	(1,520,176)
Long-term borrowings	0	0
Deferred tax liabilities	(9,196)	(2,376)
Pension and postretirement benefit liabilities	0	0
Noncurrent liability for uncertain tax positions	0	0
Notes payable and other amounts due to consolidated subsidiaries	(5,654,132)	(5,698,794)
Noncurrent contingent consideration	0	0
Noncurrent operating lease liabilities	0
Other liabilities	0
Total liabilities	(6,681,441)	(7,221,346)
Total shareholders' equity	(8,923,371)	(8,469,436)
Total liabilities and shareholders' equity	(15,604,812)	(15,690,782)
Parent Company
Current assets
Cash and cash equivalents	34,196	49,523
Accounts receivable, net	3,228	5,885
Accounts receivable from consolidated subsidiaries	33,739	32,036
Inventories, net	0	0
Prepaid expenses and other current assets	40,513	30,458
Prepaid taxes	19,518	7,029
Total current assets	131,194	124,931
Property, plant and equipment, net	2,889	3,385
Operating lease assets	13,136
Goodwill	0	0
Intangible assets, net	75	90
Investments in affiliates	5,824,869	5,984,566
Deferred tax assets	6,850	0
Notes receivable and other amounts due from consolidated subsidiaries	1,959,149	2,337,737
Other assets	42,666	17,180
Total assets	7,980,828	8,467,889
Current liabilities
Current borrowings	0	36,625
Accounts payable	3,004	3,448
Accounts payable to consolidated subsidiaries	284,386	1,058,008
Accrued expenses	6,287	5,659
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	19,772	17,156
Accrued interest	19,658	5,995
Income taxes payable	0	0
Other current liabilities	4,049	843
Total current liabilities	337,156	1,127,734
Long-term borrowings	1,949,068	2,072,200
Deferred tax liabilities	0	87,671
Pension and postretirement benefit liabilities	30,594	49,290
Noncurrent liability for uncertain tax positions	1,162	801
Notes payable and other amounts due to consolidated subsidiaries	2,673,870	2,451,784
Noncurrent contingent consideration	0	0
Noncurrent operating lease liabilities	10,616
Other liabilities	125,386	138,431
Total liabilities	5,127,852	5,927,911
Total shareholders' equity	2,852,976	2,539,978
Total liabilities and shareholders' equity	7,980,828	8,467,889
Guarantor Subsidiaries
Current assets
Cash and cash equivalents	518	1,701
Accounts receivable, net	69,322	54,013
Accounts receivable from consolidated subsidiaries	469,533	1,122,107
Inventories, net	296,136	266,073
Prepaid expenses and other current assets	10,387	9,673
Prepaid taxes	0	0
Total current assets	845,896	1,453,567
Property, plant and equipment, net	246,496	253,037
Operating lease assets	68,830
Goodwill	1,255,976	1,254,848
Intangible assets, net	1,214,148	1,277,462
Investments in affiliates	2,138,760	1,625,464
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	3,407,412	3,347,815
Other assets	12,017	5,776
Total assets	9,189,535	9,217,969
Current liabilities
Current borrowings	0	0
Accounts payable	61,106	62,764
Accounts payable to consolidated subsidiaries	428,967	292,093
Accrued expenses	33,398	41,873
Current portion of contingent consideration	124,789	106,514
Payroll and benefit-related liabilities	35,171	44,982
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	14,849	34,916
Total current liabilities	698,280	583,142
Long-term borrowings	0	0
Deferred tax liabilities	345,670	257,522
Pension and postretirement benefit liabilities	25,887	27,454
Noncurrent liability for uncertain tax positions	7,382	7,212
Notes payable and other amounts due to consolidated subsidiaries	1,860,819	2,222,580
Noncurrent contingent consideration	44,137	131,563
Noncurrent operating lease liabilities	68,167
Other liabilities	9,619	8,204
Total liabilities	3,059,961	3,237,677
Total shareholders' equity	6,129,574	5,980,292
Total liabilities and shareholders' equity	9,189,535	9,217,969
Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	222,830	305,937
Accounts receivable, net	318,375	301,054
Accounts receivable from consolidated subsidiaries	511,784	366,033
Inventories, net	224,660	192,659
Prepaid expenses and other current assets	26,518	28,237
Prepaid taxes	9,760	5,434
Total current assets	1,313,927	1,199,354
Property, plant and equipment, net	180,183	176,344
Operating lease assets	33,227
Goodwill	975,354	991,731
Intangible assets, net	961,450	1,047,500
Investments in affiliates	924,448	837,899
Deferred tax assets	5,298	4,822
Notes receivable and other amounts due from consolidated subsidiaries	287,571	13,242
Other assets	10,173	12,023
Total assets	4,691,631	4,282,915
Current liabilities
Current borrowings	50,000	50,000
Accounts payable	36,520	40,497
Accounts payable to consolidated subsidiaries	301,703	170,075
Accrued expenses	51,884	50,019
Current portion of contingent consideration	10,379	30,363
Payroll and benefit-related liabilities	44,888	42,532
Accrued interest	28	36
Income taxes payable	6,356	5,943
Other current liabilities	11,282	2,291
Total current liabilities	513,040	391,756
Long-term borrowings	0	0
Deferred tax liabilities	132,471	265,404
Pension and postretirement benefit liabilities	15,535	16,170
Noncurrent liability for uncertain tax positions	2,540	2,705
Notes payable and other amounts due to consolidated subsidiaries	1,119,443	1,024,430
Noncurrent contingent consideration	27,575	35,807
Noncurrent operating lease liabilities	25,353
Other liabilities	61,877	57,499
Total liabilities	1,897,834	1,793,771
Total shareholders' equity	2,793,797	2,489,144
Total liabilities and shareholders' equity	$ 4,691,631	$ 4,282,915

Condensed consolidating guara_6

Condensed consolidating guarantor financial information - Cash Flows (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	$ 289,167	$ 302,944
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(83,797)	(55,751)
Proceeds from sale of assets and investments	3,135	0
Payments for businesses and intangibles acquired, net of cash acquired	(1,265)	(22,550)
Net interest proceeds on swaps designated as net investment hedges	8,330	0
Investments in affiliates	0
Net cash used in investing activities from continuing operations	(73,597)	(78,301)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	25,000	0
Reduction in borrowings	(185,500)	(98,500)
Debt extinguishment, issuance and amendment fees	(4,964)	(188)
Net proceeds from share based compensation plans and the related tax impacts	14,014	18,666
Payments for contingent consideration	(112,006)	(73,152)
Proceeds from Issuance or Sale of Equity	0
Dividends paid	(47,071)	(46,526)
Intercompany transactions	0	0
Intercompany dividends paid	0	0
Net cash used in financing activities from continuing operations	(310,527)	(199,700)
Cash flows from discontinued operations:
Net cash provided by (used in) operating activities	2,651	(701)
Net cash provided by (used in) discontinued operations	2,651	(701)
Effect of exchange rate changes on cash and cash equivalents	(7,311)	(1,524)
Net (decrease) increase in cash and cash equivalents	(99,617)	22,718
Cash and cash equivalents at the beginning of the period	357,161	333,558
Cash and cash equivalents at the end of the period	257,544	356,276
Eliminations
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(253,491)	(145,626)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	0	0
Proceeds from sale of assets and investments	(2,362)	(28,239)
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Net interest proceeds on swaps designated as net investment hedges	0
Investments in affiliates	146
Net cash used in investing activities from continuing operations	(2,216)	(28,239)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0	0
Proceeds from Issuance or Sale of Equity	(146)
Dividends paid	0	0
Intercompany transactions	2,362	28,239
Intercompany dividends paid	253,491	145,626
Net cash used in financing activities from continuing operations	255,707	173,865
Cash flows from discontinued operations:
Net cash provided by (used in) operating activities	0	0
Net cash provided by (used in) discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net (decrease) increase in cash and cash equivalents	0	0
Cash and cash equivalents at the beginning of the period	0	0
Cash and cash equivalents at the end of the period	0	0
Parent Company
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(72,369)	(202,209)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(460)	(1,524)
Proceeds from sale of assets and investments	2,362	28,239
Payments for businesses and intangibles acquired, net of cash acquired	0	(100)
Net interest proceeds on swaps designated as net investment hedges	8,330
Investments in affiliates	0
Net cash used in investing activities from continuing operations	10,232	26,615
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	25,000
Reduction in borrowings	(185,500)	(98,500)
Debt extinguishment, issuance and amendment fees	(4,964)	(188)
Net proceeds from share based compensation plans and the related tax impacts	14,014	18,666
Payments for contingent consideration	0	0
Proceeds from Issuance or Sale of Equity	0
Dividends paid	(47,071)	(46,526)
Intercompany transactions	242,049	312,806
Intercompany dividends paid	0	0
Net cash used in financing activities from continuing operations	43,528	186,258
Cash flows from discontinued operations:
Net cash provided by (used in) operating activities	3,282	(701)
Net cash provided by (used in) discontinued operations	3,282	(701)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net (decrease) increase in cash and cash equivalents	(15,327)	9,963
Cash and cash equivalents at the beginning of the period	49,523	37,803
Cash and cash equivalents at the end of the period	34,196	47,766
Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	342,912	321,389
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(57,131)	(23,686)
Proceeds from sale of assets and investments	2,046	0
Payments for businesses and intangibles acquired, net of cash acquired	(1,025)	0
Net interest proceeds on swaps designated as net investment hedges	0
Investments in affiliates	(146)
Net cash used in investing activities from continuing operations	(56,256)	(23,686)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	(15,122)	(10,748)
Proceeds from Issuance or Sale of Equity	0
Dividends paid	0	0
Intercompany transactions	(272,773)	(294,600)
Intercompany dividends paid	0	0
Net cash used in financing activities from continuing operations	(287,895)	(305,348)
Cash flows from discontinued operations:
Net cash provided by (used in) operating activities	0	0
Net cash provided by (used in) discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net (decrease) increase in cash and cash equivalents	(1,239)	(7,645)
Cash and cash equivalents at the beginning of the period	1,757	8,933
Cash and cash equivalents at the end of the period	518	1,288
Non-Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	272,115	329,390
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(26,206)	(30,541)
Proceeds from sale of assets and investments	1,089	0
Payments for businesses and intangibles acquired, net of cash acquired	(240)	(22,450)
Net interest proceeds on swaps designated as net investment hedges	0
Investments in affiliates	0
Net cash used in investing activities from continuing operations	(25,357)	(52,991)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	(96,884)	(62,404)
Proceeds from Issuance or Sale of Equity	146
Dividends paid	0	0
Intercompany transactions	28,362	(46,445)
Intercompany dividends paid	(253,491)	(145,626)
Net cash used in financing activities from continuing operations	(321,867)	(254,475)
Cash flows from discontinued operations:
Net cash provided by (used in) operating activities	(631)	0
Net cash provided by (used in) discontinued operations	(631)	0
Effect of exchange rate changes on cash and cash equivalents	(7,311)	(1,524)
Net (decrease) increase in cash and cash equivalents	(83,051)	20,400
Cash and cash equivalents at the beginning of the period	305,881	286,822
Cash and cash equivalents at the end of the period	$ 222,830	$ 307,222

Subsequent Events (Details)

Subsequent Events (Details) - 5.25% Senior Notes due 2024 - Senior Notes - USD ($)	Nov. 15, 2019	Dec. 31, 2019	Oct. 31, 2019	Sep. 29, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Debt instrument, face amount					$ 250,000,000
Debt instrument, stated interest rate				5.25%
Subsequent event
Subsequent Event [Line Items]
Debt instrument, face amount			$ 250,000,000
Debt instrument, stated interest rate			5.25%
Debt instrument, redemption price, percentage of principal amount redeemed	102.625%
Loss on extinguishment of debt		$ 8,800,000

Uncategorized Items - tfx-20190

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 3,076,000
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	(1,321,000)
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	3,076,000
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (1,321,000)